

Bibliography of First Call Reports and Commentaries by Winton Gibbons

1. Sangamo Shows Solid Progress but Cash Will Still Be King, SGMO, 4 pages, 7/20/05
2. Genentech Produces Strong Quarterly Results to Go With String of Strong Data, DNA, 9 pages, 7/12/05
3. Cepheid Could Open Higher Due to Renewed Concerns Over Terrorism, CPHD, 3 pages, 7/7/05
4. Invitrogen: Acquisitions Could Add \$0.60 to EPS by 2007; Implications From Investor Meeting, IVGN, 12 pages, 6/20/05
5. Dade Behring/Applied Biosystems :Is It Time to Revisit Impact of Foreign-exchange Rates on Moderate Growth Stocks?, DADE, 10 pages, 6/20/05
6. Genentech: Another Missed Buying Opportunity? Company Buys Plant From Biogen Idec, DNA, 4 pages, 6/17/05
7. Invitrogen: Convertibles Likely Lower Interest Rate and Imply Strong Acquisition Pipeline, IVGN, 5 pages, 6/14/05
8. Biogen Idec: We Still Don't Get It; How Will Tysabri Come Back Near-term?, BIIB, 5 pages, 6/10/05
9. J&J to Begin Phase III Trials for Two Antibodies Derived From Medarex Platform, MEDX, 5 pages, 6/9/05
10. SeraCare: Initiating Coverage of Promising Small-cap Life Sciences Company, SRLS, 7 pages, 6/6/05
11. Biogen Idec: Tysabri Rumors Create More Noise; Focus Should be on Core Business, BIIB, 4 pages, 6/2/05
12. Biosite: For Stroke, Investor Focus Should Be on When and What Ramp-up, not If, BSTE, 11 pages, 6/1/05
13. Genentech: Vision Improves on Average for Patients on Lucentis, DNA, 7 pages, 5/24/05
14. Positive Phase II Clinical Data in BPH for Threshold's Lonidamine, THLD, 5 pages, 5/23/05
15. Circle the Wagons: ABI Appears to Face Impending Direct Attacks From Roche, ABI, 5 pages, 5/19/05
16. Invitrogen Acquires Another Antibody Company, \$0.02 Accretive to 2006 EPS, IVGN, 5 pages, 5/16/05
17. Thoughts on Adeza From 2005 ACOG Meeting, ADZA, 5 pages, 5/12/05
18. And Then There Were 23: Another Medarex Antibody Enters Human Trials, MEDX, 4 pages, 5/11/05
19. Medarex: Takeaways From Quarter and Call, MEDX, 5 pages, 5/10/05
20. Cepheid's First Quarter on Track, but GBS on GeneXpert Likely Delayed Two to Three Quarters, CPHD, 6 pages, 5/5/05
21. Adeza off to Strong Start with Still Many Marketing Plans in 2005, ADZA, 9 pages, 5/4/05
22. Threshold Pharmaceuticals On Track; Maintain Outperform Rating, THLD, 4 pages, 5/3/05
23. Medarex Collaborator Genmab Scores Preclinical Deal With Serono, MEDX, 4 pages, 5/2/05
24. Celera Enters the Clinic: Will Applera Restructure?, CRA, 4 pages, 5/2/05
25. Sangamo Continues to Make Good Early-stage Progress With Its Limited Cash, SGMO, 4 pages, 4/29/05
26. Invitrogen Raises 2005 Guidance After Good Start in First Quarter, IVGN, 7 pages, 4/29/05
27. Dade Behring: First Look at Strong First Quarter 2005, DADE, 8 pages, 4/29/05
28. Biogen Idec Back to Rituxan and Avonex, BIIB, 5 pages, 4/28/05
29. Continued Progress on Celera's Early-stage Pipeline, Emphasis on Early Stage, CRA, 5 pages, 4/28/05
30. Applied Biosystems: Few Catalysts Warrant Changing Negative Financial/Fundamental Outlook, ABI, 10 pages, 4/26/05
31. Yet Again, Good Early Data for DNA: Herceptin in Adjuvant Breast Cancer, DNA, 7 pages, 4/26/05
32. Medarex Pipeline Continues to Progress; Reiterate Outperform Rating, MEDX, 6 pages, 4/22/05
33. Biosite Puts Stroke on Hold, but BNP Competition Still MIA, BSTE, 13 pages, 4/22/05
34. Genentech: New Data Supports Conjecture That Dosing May Be Key to Tarceva Broad Use, DNA, 5 pages, 4/20/05
35. Genentech: Does String of Positive Avastin Data Bolster View of Another Strong Mechanism?, DNA, 6 pages, 4/15/05
36. DNA: Strong First Quarter 2005 Results Ahead of ASCO Meeting Next Month, DNA, 8 pages, 4/12/05
37. IVGN/CPHD: Invitrogen Formalizes New BioDefense Product Line With Agilent, IVGN, 4 pages, 4/7/05
38. Genentech: Rituxan Shows Positive Phase III Result in Rheumatoid Arthritis, DNA, 3 pages, 4/6/05
39. Adeza: Buying Opportunity, ADZA, 3 pages, 4/6/05
40. DNA: Avastin Competitor From Novartis Shows Mediocre Results in Phase III Trial, DNA, 7 pages, 3/21/05
41. Medarex: Management Presentation and Meetings Increase Our Conviction, MEDX, 6 pages, 3/17/05
42. Initiating Coverage of Threshold Pharmaceuticals With Outperform Rating, THLD, 8 pages, 3/17/05
43. Cepheid Should Still Benefit From Anthrax Scare at Pentagon, CPHD, 3 pages, 3/16/05
44. Genentech: Positive Avastin Data in Lung Cancer Drives Stock and Estimates, DNA, 7 pages, 3/15/05

45. Invitrogen: Reiterate Outperform Rating With Extensive Update Report, IVGN, 17 pages, 3/14/05
46. Medarex: Catalysts for 2005; Upward Inflection Point Continues, MEDX, 6 pages, 3/14/05
47. Invitrogen: Life Sciences Leader Poised for Growth in 2005 and Beyond, IVGN, 46 pages, 3/11/05
48. Adeza Biomedical: First Reported Quarter as Public Company and Outlook Quite Solid, ADZA, 8 pages, 3/10/05
49. Adeza Biomedical: First Reported Quarter as Public Company and Outlook Quite Solid, ADZA, 8 pages, 3/10/05
50. Five Important, Possibly Less Conspicuous Conclusions on Fundamental Issues, DNA, 9 pages, 3/8/05
51. Five Important, Possibly Less Conspicuous Conclusions on Fundamental Issues, DNA, 9 pages, 3/8/05
52. Genentech: Are the EGFR Wars Over? Not Quite Yet, DNA, 5 pages, 3/3/05
53. Neutral on Broader Biotech Impact of Tysabri Recall, BIIB, 6 pages, 3/3/05
54. Genentech: Are the EGFR Wars Over? Not Quite Yet, DNA, 5 pages, 3/3/05
55. Neutral on Broader Biotech Impact of Tysabri Recall, BIIB, 6 pages, 3/3/05
56. Biosite: Stroke Test by diaDexus not a Threat, BSTE, 5 pages, 3/2/05
57. Biosite: Stroke Test by diaDexus not a Threat, BSTE, 5 pages, 3/2/05
58. Cepheid Reports Strong Top-line Results; Profitability Pushed to 2006, CPHD, 5 pages, 3/1/05
59. Cepheid Reports Strong Top-line Results; Profitability Pushed to 2006, CPHD, 5 pages, 3/1/05
60. Medarex: Amgen Enters Third Medarex Antibody Into Human Clinical Trials, MEDX, 6 pages, 2/24/05
61. Medarex: Amgen Enters Third Medarex Antibody Into Human Clinical Trials, MEDX, 6 pages, 2/24/05
62. Dade Behring: Consistent (Currency-enhanced) Revenue Growth Should Drive 2005, DADE, 10 pages, 2/23/05
63. Dade Behring: First Look and Analysis of Fourth Quarter 2004, DADE, 7 pages, 2/23/05
64. Dade Behring: Consistent (Currency-enhanced) Revenue Growth Should Drive 2005, DADE, 10 pages, 2/23/05
65. Dade Behring: First Look and Analysis of Fourth Quarter 2004, DADE, 7 pages, 2/23/05
66. Sangamo: Year-end Results Show Substantial Progress in 2004; Encouraging Outlook in 2005, SGMO, 4 pages, 2/18/05
67. Invitrogen Beats Estimates; Remain Bullish on 2005 Inflection Point, IVGN, 7 pages, 2/18/05
68. Sangamo: Year-end Results Show Substantial Progress in 2004; Encouraging Outlook in 2005, SGMO, 4 pages, 2/18/05
69. Invitrogen Beats Estimates; Remain Bullish on 2005 Inflection Point, IVGN, 7 pages, 2/18/05
70. Invitrogen Makes Footprint Acquisition in Molecular Diagnostics and Cell Separation, IVGN, 7 pages, 2/9/05
71. Invitrogen Makes Footprint Acquisition in Molecular Diagnostics and Cell Separation, IVGN, 7 pages, 2/9/05
72. Biogen Idec: Tysabri Launch Trajectory Still the Story in 2005, BIIB, 7 pages, 2/8/05
73. Biogen Idec: Tysabri Launch Trajectory Still the Story in 2005, BIIB, 7 pages, 2/8/05
74. Sangamo: More Deals? Deal With Pfizer, New VP of Business Development, SGMO, 4 pages, 1/5/05
75. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends, and Catalysts, PFE, 13 pages, 12/21/04
76. Weekly Relevant Diagnostics/Life Sciences Perspectives, Trends, and Catalysts, IVGN, 10 pages, 12/20/04
77. William Blair & Company 2005 Health Care Stock Picks, PFE, 7 pages, 12/14/04
78. Invitrogen Analyst Meeting Confirms Our Optimism, IVGN, 9 pages, 12/10/04
79. Invitrogen Looks to Enter Third Business--BioMarkers (Diagnostics)--Deal With Mayo, IVGN, 4 pages, 12/7/04
80. Weekly Relevant Life Sciences/Diagnostics Perspectives, Trends, Catalysts, and Foreign Exchange Impact, ABI, 14 pages, 12/6/04
81. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends and Catalysts, PFE, 16 pages, 12/6/04
82. Future Cardiac Testing Wars?, DADE, 7 pages, 12/2/04
83. Can Genentech Double Its NHL Franchise? Focus on Fc Receptors, DNA, 7 pages, 12/2/04
84. Biogen: Tysabri (Antegren) Approved; Data Now Available, BIIB, 4 pages, 11/24/04
85. Weekly Diagnostics/Life Sciences Perspectives, Trends, Catalysts, and Foreign Exchange, IVGN, 10 pages, 11/22/04
86. Genentech: Tarceva Approved Two Months Early, DNA, 5 pages, 11/19/04
87. Invitrogen: Two Pieces of Good News--One Expected, One Not, IVGN, 6 pages, 11/19/04
88. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends, and Catalysts, PFE, 11 pages, 11/16/04
89. Weekly Diagnostics/Life Sciences Perspectives, Trends, Catalysts, and Foreign-exchange Trend, IVGN, 12 pages, 11/15/04
90. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends, and Catalysts, PFE, 11 pages, 11/15/04

91. Biosite Sued by Roche over Mainstream Patents Critical to Roche, BSTE, 7 pages, 11/15/04
92. Genentech CFO Lou Lavigne to Retire March 2005, DNA, 3 pages, 11/10/04
93. Weekly Diagnostics/Life Sciences Perspectives, Trends, Catalysts, and Foreign-exchange Impact, IVGN, 13 pages, 11/9/04
94. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends, and Catalysts, PFE, 15 pages, 11/9/04
95. Genentech Adds Sixth Early-stage Potential Therapeutic, DNA, 4 pages, 11/9/04
96. Brief Phase III Data Released on Biogen Idec's Antegren, BIIB, 3 pages, 11/8/04
97. Beyond BDS; Cepheid Hosts Upbeat Analyst Day, CPHD, 7 pages, 11/5/04
98. Sangamo: Still Two Years Cash; Intending IND for HIV Year-end 2005, SGMO, 4 pages, 11/4/04
99. Cepheid: Strong Quarter, 2004 Sales Guidance; Phase II USPS Installs May Be Lower, CPHD, 6 pages, 11/3/04
100. Two More Pieces of Good News: Rituxan in RA and Avastin Outside CRC, DNA, 9 pages, 11/2/04
101. Dade Behring: Tax Rate Helps Third Quarter; Long-term Goals Foresee Low Sales Growth, DADE, 8 pages, 11/1/04
102. Dade Behring: Tax Rate Helps Third Quarter; Long-term Goals Foresee Low Sales Growth, DADE, 8 pages, 11/1/04
103. Weekly Diagnostics/Life Sciences Perspectives, Trends, Catalysts, and Foreign-exchange Impact, IVGN, 15 pages, 11/1/04
104. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends, and Catalysts, PFE, 14 pages, 11/1/04
105. Fine-tuning of Therapeutics/Life Sciences Stocks Ahead of Election, IVGN, 7 pages, 11/1/04
106. Invitrogen: Promising Outlook in 2005 Illustrated by Robust Third-quarter Performance, IVGN, 13 pages, 10/29/04
107. Invitrogen Makes Small Acquisition for \$35 Million in Cash, IVGN, 3 pages, 10/28/04
108. Despite Revenue Miss, Biogen Beats EPS Estimate, BIIB, 6 pages, 10/28/04
109. Despite Revenue Miss, Biogen Beats EPS Estimate, BIIB, 6 pages, 10/28/04
110. Biosite: Short-term Risk Remains Despite Strong Quarter, BSTE, 10 pages, 10/27/04
111. Weekly Relevant Biotech/Pharmaceutical Perspectives, Trends and Catalysts, PFE, 16 pages, 10/26/04
112. Weekly Relevant Diagnostics/Life Sciences Perspectives, Trends and Foreign Exchange Impact, IVGN, 14 pages, 10/26/04
113. Biosite Formalizes Existing Senior Management Roles With Title Changes, BSTE, 3 pages, 10/26/04
114. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Foreign Exchange Impact, IVGN, 12 pages, 10/26/04
115. Weekly Relevant Biotech/Pharmaceutical Trends, Catalysts, and Information, DNA, 13 pages, 10/26/04
116. Applied Biosystems: Revenue Disappoints Again; Cost Cutting and Foreign Exchange Bail Out EPS, ABI, 7 pages, 10/26/04
117. Genentech: Buying Opportunity on No-news Sell-off, DNA, 4 pages, 10/26/04
118. Weekly Relevant Biotech/Pharmaceutical Trends, Catalysts, and Information, DNA, 13 pages, 10/18/04
119. Biosite: Beyond BNP--Company Hosts R&D Day to Discuss Product Pipeline, BSTE, 4 pages, 10/14/04
120. Genentech Buying Opportunity Despite Strong Quarter and Robust Position, DNA, 3 pages, 10/7/04
121. Weekly Relevant Biotech / Pharmaceutical Trends and Information, DNA, 13 pages, 10/5/04
122. Genentech Receives Subpoena Related to Promotion of Rituxan, DNA, 3 pages, 10/5/04
123. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Fx, IVGN, 11 pages, 10/4/04
124. Sangamo Announces Collaboration With Johnson & Johnson, SGMO, 4 pages, 9/30/04
125. Genentech: Tarceva Accepted by FDA with Fast-track Status and January 30 Action Date, DNA, 3 pages, 9/30/04
126. Genentech and Celera Enter Cancer Collaboration, DNA, 6 pages, 9/28/04
127. Dade Behring Launches CHF (NT-proBNP) Test Early, DADE, 3 pages, 9/28/04
128. Cepheid Launches ASR Medical Diagnostic Products, CPHD, 5 pages, 9/28/04
129. DNA/BIIB: For Psoriasis, Allergan Gets Non-approvable Letter for Tazarotene, BIIB, 3 pages, 9/27/04
130. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 14 pages, 9/27/04
131. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Fx Impact, IVGN, 12 pages, 9/27/04
132. Genentech: Shows Conviction, Announces Manufacturing Deal for Herceptin With Wyeth, DNA, 4 pages, 9/24/04
133. Genentech: Raptiva Approved in Europe Union for Psoriasis, DNA, 3 pages, 9/23/04
134. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign-exchange Impact, IVGN, 11 pages, 9/21/04

135. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 11 pages, 9/21/04
136. Genentech: More Positive Survival Data for Tarceva in Pancreatic Cancer, DNA, 3 pages, 9/20/04
137. Sangamo Announces HIV Program Ahead of Investor Meeting, SGMO, 3 pages, 9/14/04
138. Genentech Provides Tarceva to Patients Through "Compassionate-use" Trial, DNA, 3 pages, 9/10/04
139. Dade Behring: For Heart Attack--Platelet Test Appears Incremental to Protein Markers, DADE, 7 pages, 9/9/04
140. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 12 pages, 9/7/04
141. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Currency Update, IVGN, 10 pages, 9/7/04
142. FDA Postpones Decision on Generic Growth Hormone, PFE, 3 pages, 9/3/04
143. Sangamo Collaborator Edwards Announces First Patient Dosed in Clinical Trial, SGMO, 3 pages, 8/31/04
144. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Currency Update, IVGN, 9 pages, 8/27/04
145. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 12 pages, 8/27/04
146. Weekly Relevant Diagnostics/Life Sciences Trends, IVGN, 9 pages, 8/26/04
147. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 8/26/04
148. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 8/16/04
149. Weekly Relevant Diagnostics/Life Sciences Trends, IVGN, 8 pages, 8/13/04
150. Genentech and FDA Issue Safety Warning on Avastin, DNA, 3 pages, 8/13/04
151. Sangamo Deepens Clinical Development Expertise; Hires Chief Medical Officer, SGMO, 5 pages, 8/10/04
152. Cepheid Stock Weakness Today Creates Buying Opportunity, CPHD, 4 pages, 8/9/04
153. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Fx Update, IVGN, 9 pages, 8/9/04
154. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 8/9/04
155. USPS BDS Redeployment Provides Revenue Upside for Cepheid, CPHD, 5 pages, 8/5/04
156. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Foreign Currency Update, IVGN, 13 pages, 8/3/04
157. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 11 pages, 8/3/04
158. Biosite: Clinical Trial on Track, Update on Promising Panel for Stroke, BSTE, 6 pages, 8/2/04
159. Biosite: Quarter as Preannounced/Competitive Wave Now 1Q05/Stroke Panel Finally Set, BSTE, 7 pages, 7/30/04
160. Celera: String of Early-stage Drug News and Strong Cash Position, CRA, 5 pages, 7/29/04
161. Dade Behring: Unexpected Jump in Gross Profit Margins Drive EPS Upside, DADE, 7 pages, 7/28/04
162. Applied Biosystems: Quarter a Mixed Bag, but Met Bottom Line, ABI, 7 pages, 7/28/04
163. Biogen Idec Reports Solid Second Quarter, BIIB, 5 pages, 7/28/04
164. Dade Behring's NT-proBNP FDA-cleared but Delayed; Upside for Biosite, DADE, 3 pages, 7/27/04
165. Celera Genomics Gets Milestone Payment From Merck, CRA, 3 pages, 7/26/04
166. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 10 pages, 7/26/04
167. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Fx Update, IVGN, 12 pages, 7/26/04
168. Sangamo's Second Quarter Is Positive, As Expected; No News, SGMO, 7 pages, 7/23/04
169. Large Overreaction to Minor Revenue Miss: Invitrogen Still Best of Breed, IVGN, 9 pages, 7/21/04
170. Invitrogen: Second Quarter 2004 First Look, IVGN, 6 pages, 7/21/04
171. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 7/19/04
172. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Exchange Update, IVGN, 10 pages, 7/19/04
173. Not Surprising, Biosite Preannounces Strong Second-quarter Results; We Remain Cautious, BSTE, 6 pages, 7/16/04
174. Sangamo: Reiterate Outperform Rating; Stock Weakness Creates Buying Opportunity, SGMO, 6 pages, 7/15/04
175. June 2004 Earnings Preview: Biotech, Pharmaceuticals, Life Sciences and Diagnostics, PFE, 19 pages, 7/15/04
176. Applied Biosystems Strategic Reorganization Announced in 8-K Filing, ABI, 5 pages, 7/14/04
177. Invitrogen Creates New Biodefense Subsidiary Based in Maryland, IVGN, 5 pages, 7/14/04
178. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Fx Update, IVGN, 9 pages, 7/12/04
179. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 7/12/04
180. Avastin Revenues Lead Strong Second Quarter for Genentech, DNA, 9 pages, 7/8/04
181. Promising But Early Stage, Celera Genomics Announces Deal With Abbott, CRA, 3 pages, 7/7/04

182. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign-exchange Update, IVGN, 10 pages, 7/6/04
183. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 12 pages, 7/6/04
184. Biosite: FDA Clears Biosite's New Shortness-of-breath Test, BSTE, 5 pages, 6/30/04
185. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 6/28/04
186. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Foreign Exchange, IVGN, 10 pages, 6/28/04
187. Cepheid: Menu, Menu, Menu--Upgrading to Outperform, CPHD, 7 pages, 6/25/04
188. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 6/21/04
189. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Currency, IVGN, 9 pages, 6/21/04
190. Biosite: Eye of the Needle or Eye of the Storm?, BSTE, 25 pages, 6/16/04
191. Sangamo: Entering the Clinic, SGMO, 20 pages, 6/15/04
192. Cepheid: Pleased With Promising Product Pipeline Plus Postal Potential, CPHD, 18 pages, 6/15/04
193. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 10 pages, 6/15/04
194. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Exchange, IVGN, 10 pages, 6/15/04
195. Genentech Stock Weakness Creates Modest Buying Opportunity, DNA, 8 pages, 6/10/04
196. Cepheid Announces USPS Resumes BDS Installations, CPHD, 5 pages, 6/8/04
197. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 9 pages, 6/7/04
198. Weekly Relevant Diagnostics/Life Sciences Trends, Information, and Foreign Exchange Update, IVGN, 9 pages, 6/7/04
199. Sangamo: Well Attended Gene Therapy Symposium With Promising Presentation, SGMO, 5 pages, 6/4/04
200. Weekly Relevant Biotech/Pharmaceutical Trends and Information, DNA, 14 pages, 6/2/04
201. Weekly Relevant Diagnostics/Life Sciences Trends, Information and Foreign Exchange, IVGN, 12 pages, 6/2/04
202. Diagnostics/Life Sciences Foreign Currency Trends and Valuation Update, IVGN, 9 pages, 5/25/04
203. Weekly Biotech/Pharmaceutical Updates and Valuations, DNA, 11 pages, 5/24/04
204. Weekly Biotech / Pharmaceutical Valuations, DNA, 8 pages, 5/17/04
205. Diagnostics/Life Sciences Valuations and Foreign Currency Update, IVGN, 8 pages, 5/17/04
206. Sangamo to Have Strong Presence at Gene Therapy Annual Meeting in June, SGMO, 4 pages, 5/17/04
207. Weekly Biotech Valuations, DNA, 8 pages, 5/11/04
208. Diagnostics/Life Sciences Valuations and Foreign Currency Update, IVGN, 8 pages, 5/11/04
209. Therapeutics, Diagnostics, and Life Sciences Coverage First-quarter Assessment, PFE, 21 pages, 5/10/04
210. Cepheid: Pleased With Progress; Confident USPS Delays to be Resolved Before Third Quarter, CPHD, 5 pages, 5/6/04
211. Therapeutics Valuation Update, DNA, 7 pages, 5/5/04
212. Sangamo Receives \$2 Million Advanced Technology Program Grant, SGMO, 3 pages, 5/4/04
213. Cash Short/Drifting Strategy: Dropping Coverage of LSBC Despite Viable Technology, LSBC, 3 pages, 5/4/04
214. Year-to-date Performance of Top Picks by William Blair Health Care Group Positive, PFE, 5 pages, 5/4/04
215. Foreign Currency and Diagnostics Valuation Summary, CRA, 11 pages, 5/3/04
216. Biogen Idec's Antegren Appears Well on Track for 2005 Approval, BIIB, 4 pages, 4/30/04
217. Cepheid: Reaction to Temporary Halt of BDS Deployment Likely Still Overdone, CPHD, 3 pages, 4/30/04
218. DADE: Dimension Vista Delayed By One Year, but First-quarter Operating Results Strong, DADE, 7 pages, 4/30/04
219. Cepheid: USPS Delays Further Deployment of BDS due to Performance Concerns, CPHD, 4 pages, 4/29/04
220. Biosite: In Face of Gathering Competition, Company Still Raises 2004 Guidance, BSTE, 9 pages, 4/29/04
221. Celera Diagnostics Executing Well, Although Not Possible to Invest Directly, CRA, 4 pages, 4/28/04
222. ABI: With SDS and Mass Spec More Than 50% of Revenues, Improves Marginally, ABI, 8 pages, 4/27/04
223. Celera: Lack of Human Clinical Trials Prompts Rating Change to Market Perform, CRA, 5 pages, 4/27/04
224. Genentech: Tarceva Launch Likely in First Quarter 2005; DNA's First Small-molecule Drug, DNA, 6 pages, 4/27/04
225. Foreign Currency and Diagnostics Valuation Summary, DADE, 6 pages, 4/26/04
226. Genentech Meets Survival Endpoint in Phase III Trial of Tarceva in Lung Cancer, DNA, 4 pages, 4/26/04
227. Invitrogen Has Strong Operational Start to 2004, IVGN, 9 pages, 4/23/04

228. Therapeutics, Life Sciences, and Diagnostics Earnings Preview; Invitrogen Upgrade, IVGN, 24 pages, 4/20/04
229. Diagnostics/Life Sciences Valuations and Foreign Currency Update, BSTE, 7 pages, 4/12/04
230. Genentech Off to Strong Start as Expected; Positive Outlook Unchanged, DNA, 11 pages, 4/8/04
231. Biosite Preannounces Quite Strong First-quarter Results; Our Cautious 12-month Outlook Is Unchanged, BSTE, 5 pages, 4/8/04
232. Amersham: Dropping Coverage as GE Closes Acquisition, AHM, 3 pages, 4/8/04
233. Biosite Stock Strength on Value Buying and Short Covering, BSTE, 5 pages, 4/6/04
234. Cepheid Gets FDA Clearance for Second Clinical Genetic Test, MRSA, CPHD, 4 pages, 3/23/04
235. Genentech: Perspective on Upbeat Analyst Meeting, DNA, 8 pages, 3/16/04
236. Biosite Announces Second Discovery Collaboration, BSTE, 5 pages, 3/8/04
237. Biogen Idec Shows Solid Foundation After Merger, BIIB, 5 pages, 3/3/04
238. Therapeutics, Diagnostics, and Life Sciences Coverage: December Quarter Earnings Review, PFE, 21 pages, 2/27/04
239. More Perspective on the Biosite License of MPO, a New Cardiac Marker to Assess Risk of Major Heart Events, BSTE, 6 pages, 2/27/04
240. New Cepheid Model; Expect Substantial Revenue Growth and Pipeline Progress, CPHD, 9 pages, 2/27/04
241. Dade: Expect Ongoing Double-digit EPS Growth but with Revenue Growth Slowing to Low Single-digits by 2005, DADE, 6 pages, 2/20/04
242. Dade Behring: First Look at Fourth-quarter Results; Operating Income In Line, DADE, 6 pages, 2/20/04
243. Sangamo: Fourth-quarter Earnings Review; Company Enters the Clinic, SGMO, 5 pages, 2/12/04
244. Invitrogen: First Look, IVGN, 5 pages, 2/12/04
245. Sangamo Enters the Clinic; Raising Rating to Outperform, SGMO, 4 pages, 2/11/04
246. Biosite: Additional Thoughts on Stroke Diagnostic; Potential Market Large but Challenging, BSTE, 5 pages, 2/10/04
247. Diagnostics/Life Sciences Valuations and Foreign Currency Weekly Update, Including Roche Highlights, DADE, 7 pages, 2/10/04
248. Biosite: Provides Enthusiastic Update Regarding Triage Stroke, BSTE, 5 pages, 2/5/04
249. Biosite: Abbott's BNP Test Gets FDA Clearance; Biosite/Beckman Have Only 1-2 Months' Head Start, BSTE, 4 pages, 2/3/04
250. Diagnostics/Life Sciences Valuations and Foreign Currency Weekly Update, DADE, 7 pages, 2/3/04
251. Biosite: New Discovery Agreement With Amylin, BSTE, 3 pages, 2/2/04
252. Applied Biosystems: Beats Street by Two Cents, but Misses Our Estimate by a Penny, ABI, 5 pages, 1/28/04
253. Despite Significant Revenue Upside, Biosite Misses Our Fourth-quarter Estimate by a Nickel, BSTE, 8 pages, 1/27/04
254. Diagnostics/Life Sciences Valuations and Foreign Currency Weekly Update, BSTE, 9 pages, 1/21/04
255. DNA: Strong Portfolio of Products with Consistent Growth, New Product Momentum and Two Potential Blockbuster Indications, DNA, 9 pages, 1/15/04
256. Dade Licenses Early-stage, Novel Marker for Carotid Stenosis, DADE, 3 pages, 1/13/04
257. Applied Biosystems: Favorable Foreign Currency Better Boost Revenue With Mid-to-long-term Fundamentals Difficult, ABI, 7 pages, 1/9/04
258. Cepheid: Strategic Diagnostic Partner Revealed--bioMerieux, CPHD, 6 pages, 1/6/04
259. Biosite: Short-term Momentum to Give Way to Midyear Vulnerability, BSTE, 6 pages, 12/31/03
260. Invitrogen: Concerns Alleviated, We Favor the BioReliance Acquisition, IVGN, 6 pages, 12/29/03
261. Invitrogen Purchases BioReliance, a Provider of Contract Manufacturing and Services to Biotech Companies, IVGN, 4 pages, 12/24/03
262. Dade Behring Holdings: Diagnostics Pure-play Poised for 20% Earnings Growth, DADE, 35 pages, 12/19/03
263. Sangamo: Critical Milestone to Occur Earlier Than Recent Expectations, SGMO, 3 pages, 12/18/03
264. Invitrogen EPS Guidance In Line With Preview; Margin and Revenue Could Provide Upside, IVGN, 5 pages, 12/18/03
265. Bad News for Biosite: Abbott to Buy Point-of-care Diagnostic Company i-STAT, BSTE, 4 pages, 12/18/03
266. Genentech: Billion-dollar Share Buyback; Positive Clinical Data for Lead Drug Rituxan, DNA, 6 pages, 12/8/03
267. Celera Diagnostics Well on Track; Expect Completion of Significant Milestones in 2004, CRA, 4 pages, 12/5/03
268. ABI Situation Still Difficult; Continue to Prefer Invitrogen as Stock to Own in Life Sciences, ABI, 6 pages, 12/4/03

269. Genentech: Small Avastin Trial Not Fundamental to FDA Clearance or Stock, DNA, 3 pages, 12/4/03
270. Dade Behring: Announces \$50 Million Debt Prepayment, DADE, 3 pages, 12/4/03
271. Cepheid: The Pipeline Is Full, CPHD, 6 pages, 11/5/03
272. Information We Consider Incremental From the Dade Behring Conference Call, DADE, 4 pages, 11/3/03
273. Dade Behring: Results Mostly as Expected but Constant-currency Sales Growth off Slightly, DADE, 4 pages, 10/31/03
274. Biosite: Stock Down About 10% on Competitor Note, but No New News, BSTE, 3 pages, 10/29/03
275. Sangamo: Two INDs Expected in 2004 and Cash Position Remains Stable, SGMO, 3 pages, 10/29/03
276. Invitrogen: Cell Culture Revenues, Accretive Acquisitions, and Improving Margins Drive Strong Third-quarter Results, IVGN, 6 pages, 10/23/03
277. Biosite: Very Challenging but Doable 12- to 24-month Outlook, BSTE, 6 pages, 10/23/03
278. Cash-tight Large Scale Biology Making Minor Progress and May Now Seek Financing, LSBC, 3 pages, 10/23/03
279. Applied Biosystems: Another Quarter Without a Turnaround, ABI, 5 pages, 10/23/03
280. Cepheid Receives \$2 Million Option Payment From Strategic Partner, CPHD, 4 pages, 10/17/03
281. Dade Behring: Achieves 150-basis-point Reduction in Term Debt Interest Rate, DADE, 8 pages, 10/13/03
282. Amersham: GE Offers \$9.5 Billion in Stock to Acquire, AHM, 3 pages, 10/10/03
283. Genentech: As Expected, Another Strong Quarter for Genentech, DNA, 6 pages, 10/9/03
284. Expect Dade Behring to Maintain Momentum in the Third Quarter, DADE, 8 pages, 10/2/03
285. Celera Genomics: First Announcement of New, Genetic Markers for Medical Diagnostics, CRA, 3 pages, 9/30/03
286. Biosite: Despite Stumbling in Second Half, Should Regain Footing by End of First Quarter 2004, BSTE, 5 pages, 9/26/03
287. Biosite Doesn't Wait: Preannounces Reduced Expectations for Third Quarter and 2003, BSTE, 4 pages, 9/24/03
288. Invitrogen: Meeting With CEO Reinforces Our Optimism for the Company, IVGN, 3 pages, 9/12/03
289. Genentech: Unanimous Recommendation for Raptiva Approval From FDA Committee, DNA, 6 pages, 9/10/03
290. Genentech: Positive Patent Settlement With Amgen Reinforces Strength of Intellectual Property Estate, DNA, 3 pages, 8/28/03
291. DADE: Favorable Foreign Currency Effects Propel Strong Results, DADE, 5 pages, 8/12/03
292. Preview of Dade Behring Second-quarter; Raising Estimates, DADE, 8 pages, 8/1/03
293. Cepheid: Instrument Sales Growth Not Yet Apparent, but Potential Remains Strong, CPHD, 4 pages, 8/1/03
294. Amersham Reports Strong Midyear Results in a Tough Foreign Exchange Rate Environment, AHM, 8 pages, 7/30/03
295. Sangamo Has \$47 Million in Cash and Is On Track for IND in Mid-2004, SGMO, 5 pages, 7/29/03
296. Invitrogen Announces Sale of \$300 million of Convertible Notes, IVGN, 3 pages, 7/28/03
297. Biosite: Strong Quarters Continue; Competitive Threats Not Meaningful Until At Least 2004, BSTE, 7 pages, 7/25/03
298. Invitrogen: Outlook Improving; Foreign Currency Drives Already Strong Second Quarter; Molecular Biology Still Lacks Growth, IVGN, 7 pages, 7/25/03
299. Applied Biosystems: Final Thoughts on Quarterly Results, ABI, 4 pages, 7/24/03
300. Large Scale: Results Slightly Less Than Expected; De-Listing Averted, Cost Reductions Continue, LSBC, 3 pages, 7/24/03
301. Dade Behring: Upbeat Management Presentation Affirms Our Positive Outlook, DADE, 6 pages, 7/11/03
302. Genentech: Strong Second-quarter Results As Expected, DNA, 6 pages, 7/10/03
303. Biosite: Renews Distribution Agreement With Fisher HealthCare, BSTE, 3 pages, 7/8/03
304. Dade Behring: Initiating Coverage With Market Perform Rating, Core Growth Profile, DADE, 13 pages, 6/11/03
305. Sangamo: Favorable Preclinical Results Represent an Important Milestone, SGMO, 4 pages, 6/9/03
306. Genentech: Stock Appreciation Creates Potential Near-term Volatility, but Maintaining Outperform, DNA, 6 pages, 6/3/03
307. Biosite: Site Visit Provides Increased Confidence in Near-term Performance and Long-term Upside, BSTE, 7 pages, 6/2/03
308. Cepheid: First Part of USPS Contract Should Boost 2004 Revenue \$28 Million, CPHD, 4 pages, 5/21/03

309. Cepheid Announces Major Biodefense Contract With the United States Postal Service, CPHD, 3 pages, 5/20/03
310. Genentech: Phase II Results Positive in Ulcerative Colitis Form of Inflammatory Bowel Disease for MLN-02, DNA, 3 pages, 5/19/03
311. Genentech: Xolair Moves Significantly Closer to U.S. Market With Approval for Allergic Asthma, DNA, 4 pages, 5/16/03
312. Biosite: Announces PSS as Distributor for Physician Office Lab Market, BSTE, 4 pages, 5/15/03
313. Initiating Coverage of Amersham With an Outperform Rating, AHM, 11 pages, 5/15/03
314. Genentech: Raptiva's Early Failure in Rheumatoid Arthritis Fundamentally Neutral, but may Cause Stock Weakness, DNA, 4 pages, 5/12/03
315. Biosite: Outstanding Quarter Again Driven by BNP; Significantly Raising Estimates, BSTE, 5 pages, 5/2/03
316. Cepheid Needs Cash; First-quarter Loss Greater Than Expected, CPHD, 3 pages, 5/1/03
317. Sangamo: Delay of First IND Filing Until 2004 a Setback, SGMO, 4 pages, 4/30/03
318. Invitrogen: Stronger-than-expected Quarter With Some Help From Favorable Exchange Rates, IVGN, 5 pages, 4/25/03
319. Celera Genomics' Fiscal Third Quarter Reflects Progress in Diagnostics Business, CRA, 4 pages, 4/23/03
320. Applied Biosystems: Short-to Intermediate-term Outlook Remains Gloomy With Third-quarter Earnings as Expected, ABI, 4 pages, 4/23/03
321. Large Scale Biology: Reducing Rating to Underperform Due to Increasing Risk, LSBC, 3 pages, 4/23/03
322. Large Scale Biology: Significant Senior Management Changes, LSBC, 3 pages, 4/15/03
323. Genentech's First-quarter Results Exceed Expectations; Outlook Remains Strong, DNA, 4/10/03
324. Cepheid: Begins U.S. Shipment of New Test for Group B Strep, CPHD, 4/9/03
325. Biosite Marketing VP Gary King Presents at William Blair; ACC Recap, BSTE, 4/2/03
326. Large Scale Biology: Receives Expected Nasdaq Delisting Notice, LSBC, 3/31/03
327. Genentech: Xolair's BLA to be Reviewed by FDA Advisory Committee May 15,2003, DNA, 3/27/03
328. Genentech Weak on Competitor Downgrade--We Recommend Purchase (1/2), DNA, 3/20/03
329. Genentech Weak on Competitor Downgrade--We Recommend Purchase (2/2), DNA, 3/20/03
330. Applied Biosystems: Issues Profit Warning, ABI, 3/19/03
331. Genentech: Raising to Outperform on Increased Confidence, Valuation-1, DNA, 3/17/03
332. Genentech: Raising to Outperform on Increased Confidence, Valuation-2, DNA, 3/17/03
333. Large Scale Biology: Gains Sales/Marketing Strength in Contract Manufacturing, LSBC, 3/3/03
334. Therapeutic Antibodies: Sector Valuations Are Reasonable (2 of 3), DNA, 3/3/03
335. Therapeutic Antibodies: Sector Valuations Are Reasonable (3 of 3), DNA, 3/3/03
336. Therapeutic Antibodies: Sector Valuations Are Reasonable (1 of 3), DNA, 3/3/03
337. Valuing Therapeutic Antibodies, DNA, 46 pages, 2/28/03
338. Large Scale Biology Secures Biomanufacturing Contract With U. of Arkansas, LSBC, 2/28/03
339. Cepheid: Draws \$5 Million From Shelf Registration, Extends Need for More Cash, CPHD, 2/28/03
340. Genentech: FDA Acceptance of Raptiva's Regulatory Submission a Positive, DNA, 2/28/03
341. IVGN: Solid Prospects Remain, But Fourth Quarter Hurt by Excess Marketing Spend, IVGN, 2/14/03
342. Cepheid Enters Cancer Test Collaboration With JNJ's Ortho-Clinical Diagnostics, CPHD, 2/12/03
343. Biosite Announces Cardiovascular Research Collaboration With CIPHERGEN, BSTE, 2/11/03
344. Sangamo: Continues to Successfully Balance Cash Conservation With Development, SGMO, 2/6/03
345. Cepheid Making Progress as a Developmental Company, CPHD, 2/6/03
346. Biosite: Dade Behring Licenses NT-proBNP from Roche; Minimal Threat to Biosite, BSTE, 2/5/03
347. Invitrogen: Makes Smart Acquisition of PanVera Assets From Vertex, IVGN, 2/5/03
348. Biosite: Weakness Unreflective of Fundamentals, BSTE, 2/4/03
349. LSBC: Lack of Cash Infusion Prompts Rating Change Despite Business Development, LSBC, 1/30/03
350. Biosite: Buying Opportunity on Today's Weakness, BSTE, 1/28/03
351. Biosite: BNP Still the Story; Outlook Favorable in 2003 (Part 1), BSTE, 1/28/03
352. Biosite: BNP Still the Story; Outlook Favorable in 2003 (Part 2), BSTE, 1/28/03
353. Celera: EPS Exceeds Expectations; Development Progress Continues, CRA, 1/23/03
354. Uncertain Revenue Growth Remains the Issue for Applied Biosystems, ABI, 1/23/03
355. Large Scale Biology: FDA Grants Orphan Drug Status for Fabry Disease Treatment, LSBC, 1/23/03
356. Sangamo: Signs Research and Drug Discovery Agreement With Purdue Pharma, SGMO, 1/21/03
357. Competitor Amgen Reports Strong Phase III Efficacy for Psoriasis Drug Enbrel, BIIB, 1/17/03
358. Genentech: Top-line Momentum Continues, Driven Primarily by Rituxan (1/2), DNA, 1/16/03

359. Genentech: Top-line Momentum Continues, Driven Primarily by Rituxan (2/2), DNA, 1/16/03
360. Applied Biosystems Reduces Operating Expenses by Eliminating 9% of Workforce, ABI, 12/30/02
361. Bring on the BNP Competition: Outlook for Biosite Remains Favorable, BSTE, 19 pages, 12/20/02
362. Genentech: Update Report Issued Detailing Company Profile Change, DNA, 26 pages, 12/19/02
363. Large Scale Biology Secures Second Contract With Growers Research Group, LSBC, 12/19/02
364. Genentech's Completes Regulatory Submission for Xolair on Schedule, DNA, 12/19/02
365. Celera Genomics: Analyst Day Emphasizes Competitive Advantages, CRA, 12/18/02
366. Genentech: Report Issued Detailing Company Profile Change to Established Growth, DNA, 12/13/02
367. Cepheid, Through the Northrop Grumman Team, Awarded an Expanded Pilot Contract, CPHD, 12/13/02
368. Large Scale Biology's Strong Medical Science Platform Highlighted at ASH, LSBC, 12/11/02
369. Celera Diagnostics Wins Regulatory Clearance for HIV Test, CRA, 12/11/02
370. Invitrogen: 2003 Guidance In Line With Our Expectations, IVGN, 12/11/02
371. Large Scale Biology to Present Clinical Study Data at ASH Conference, LSBC, 12/6/02
372. Invitrogen Founder and CEO Lyle Turner Retires, IVGN, 12/6/02
373. LSBC: Agreement With Ukraine Regarding Plant-derived, Protein-based Drugs, LSBC, 12/3/02
374. Biosite: Bring on the BNP Competition; Outlook Favorable Despite Risks (2/2), BSTE, 11/27/02
375. Biosite: Bring on the BNP Competition; Outlook Favorable Despite Risks (1/2), BSTE, 11/27/02
376. Cepheid: Indemnification Hurdle to USPS Contract Should Be Obviated by New Bill, CPHD, 11/26/02
377. DNA: Diverse Product Mix, Robust Pipeline Justify Established Growth Profile--1, DNA, 11/26/02
378. DNA: Diverse Product Mix, Robust Pipeline Justify Established Growth Profile--2, DNA, 11/26/02
379. Sangamo and Edwards Lifesciences Broaden Development Agreement, SGMO, 11/20/02
380. Cepheid: SmartCycler Receives First FDA Clearance for Diagnostic Test, CPHD, 11/19/02
381. Celera: Meetings With Management Suggest Strategic Plan Progressing Well (2), CRA, 11/14/02
382. Celera: Meetings With Management Suggest Strategic Plan Progressing Well (1), CRA, 11/14/02
383. Genentech: Laying the Groundwork for the Next Wave of Growth, DNA, 11/14/02
384. Dropping Coverage of ACLARA BioSciences, Inc., ACLA, 11/13/02
385. Dropping Coverage of Genaissance Pharmaceuticals, Inc., GNSC, 11/13/02
386. Cepheid: Likelihood of USPS Contract Increases (Part 1 of 2), CPHD, 11/7/02
387. Celera Diagnostics Announces Breast Cancer Research Collaboration, CRA, 11/7/02
388. Cepheid: Likelihood of USPS Contract Increases (Part 2 of 2), CPHD, 11/7/02
389. Sangamo Publishes Positive Preclinical Results for Lead Therapeutic Program, SGMO, 11/4/02
390. Sangamo's Third-quarter Results Reflect Focus on Development (2), SGMO, 10/31/02
391. Sangamo's Third-quarter Results Reflect Focus on Development (1), SGMO, 10/31/02
392. Very Strong Third-quarter Results for Biosite; Estimate Increase (Part 3 of 3), BSTE, 10/29/02
393. Very Strong Third-quarter Results for Biosite; Estimate Increase (Part 1 of 3), BSTE, 10/29/02
394. Very Strong Third-quarter Results for Biosite; Estimate Increase (Part 2 of 3), BSTE, 10/29/02
395. Expect Limited Top-line Growth for Applied Biosystems Over Coming Fiscal Years, ABI, 10/25/02
396. Invitrogen's In-line Results Helped by Foreign Currency, Share Repurchase--I, IVGN, 10/25/02
397. Invitrogen's In-line Results Helped by Foreign Currency, Share Repurchase--II, IVGN, 10/25/02
398. Celera Genomics Posts Strong Quarterly Results (Part 2 of 2), CRA, 10/25/02
399. Celera Genomics Posts Strong Quarterly Results (Part 1 of 2), CRA, 10/25/02
400. Celera Genomics: Losses Narrow; Transition to Therapeutics Continues, CRA, 10/24/02
401. Large Scale Biology: Results Reflect Progress in Executing Business Plan, LSBC, 10/24/02
402. Sangamo Hires Vice President of Finance and Administration, SGMO, 10/22/02
403. Large Scale Biology Hires Senior Director of Business Development, LSBC, 10/17/02
404. Applied Biosystems and Cepheid Announce Collaboration to Develop Reagents, ABI, 10/16/02
405. Invitrogen Acquires Informax for \$42 Million in Cash, IVGN, 10/15/02
406. Large Scale Biology Licenses Proteomics Technology to Agilent Technologies, LSBC, 10/10/02
407. Genentech: Rituxan Continues to Fuel Top-line Momentum in Third Quarter (I), DNA, 10/10/02
408. Genentech: Rituxan Continues to Fuel Top-line Momentum in Third Quarter (II), DNA, 10/10/02
409. Celera Genomics: Brings Asthma Development Program In-house, CRA, 10/9/02
410. Large Scale Biology: Financial Award for Next-generation Vaccine Development, LSBC, 10/8/02
411. Celera Diagnostics and Bristol-Myers to Identify Disease Markers, CRA, 10/7/02
412. Celera Diagnostics to Collaborate With Two Leading Commercial Testing Labs, CRA, 10/2/02
413. Biosite: Stock Sell-off Creates Unexpected Trading Opportunity (II), BSTE, 10/2/02
414. Biosite: Stock Sell-off Creates Unexpected Trading Opportunity (I), BSTE, 10/2/02

415. Sangamo Enters Another 50/50 Gene Therapy Collaboration, This Time With Avigen, SGMO, 10/2/02
416. No USPS Contract Yet for Cepheid, CPHD, 10/1/02
417. Genentech: Phase III Pipeline Set to Expand in Early 2003, DNA, 10/1/02
418. Biosite: BNP Remains a Very Hot Topic at Well-attended HFSA Meeting (Pt 1), BSTE, 9/25/02
419. Biosite: BNP Remains a Very Hot Topic at Well-attended HFSA Meeting (Pt 2), BSTE, 9/25/02
420. Review Meeting for AstraZeneca's Iressa Represents a Net Positive for Genentech, DNA, 9/25/02
421. Genentech Receives Second Fast-track Designation for Tarceva, DNA, 9/23/02
422. Biosite Justifiably Strong: How to Navigate the Competitive Noise in 2002?, BSTE, 9/19/02
423. Large Scale Biology: Reorganizes Into Three Units, Adds New Drug to Pipeline, LSBC, 9/18/02
424. Positive Clinical News for Genentech--Raptiva Hits Primary Phase III Endpoint, DNA, 9/17/02
425. Cepheid Up on Mention of Potential Anthrax Detection Contract With U.S. Postal, CPHD, 9/13/02
426. Life Sciences, Genomics, Medical Technology: New William Blair Rating System, ABI, 9/4/02
427. Cepheid Patent Estate Strengthening for Key Product, GeneXpert, CPHD, 8/29/02
428. Initiating Coverage of Cepheid with a Long-term Buy Rating, CPHD, 8/19/02
429. Biosite Announces Discovery Deal With MedImmune, BSTE, 8/15/02
430. ACLARA BioSciences: Still-changing Business Model Prompts Lower Rating, ACLA, 8/14/02
431. Lowering Rating for Genaissance Due to Reduced Revenue Expectations, Visibility, GNSC, 8/14/02
432. Positive Phase I Results for Large Scale Biology Non-Hodgkins Lymphoma vaccine, LSBC, 8/6/02
433. Invitrogen Announces \$300 million Stock Repurchase Over Three Years, IVGN, 8/2/02
434. Biosite: Early BNP Competition Could Be Even More Benign Than We Expected, BSTE, 7/31/02
435. Biosite: Roche Files with FDA to Market NT-proBNP for Congestive Heart Failure, BSTE, 7/30/02
436. Applied Biosystems' Fourth-quarter Results; Possible Improving Outlook, ABI, 7/26/02
437. Excellent Second Quarter 2002 Results for Biosite; Increasing Estimates (Pt 2), BSTE, 7/26/02
438. Excellent Second Quarter 2002 Results for Biosite; Increasing Estimates (Pt 1), BSTE, 7/26/02
439. Excellent Second Quarter 2002 Results for Biosite; Increasing Estimates (Pt 3), BSTE, 7/26/02
440. Celera Beats Expectations; Continued Focus on Downstream Drug Discovery, CRA, 7/26/02
441. Invitrogen's Earnings Better Than Expected; Improved Gross Margins, IVGN, 7/25/02
442. Second-quarter Results Confirm Large Scale Biology Execution Improving, LSBC, 7/25/02
443. Sangamo: Second-quarter Results, SGMO, 7/25/02
444. Large Scale Biology: Announces \$12 Million, Five-year Proteomics Deal, LSBC, 7/24/02
445. Biosite BNP Clinical Trial Results Published in New England Journal of Medicine, BSTE, 7/18/02
446. Sangamo Signs Small Molecule Screening Collaboration With Icagen, SGMO, 7/17/02
447. Stryker: Outstanding Earnings; Upside Aided by Currency Comparisons, SYK, 7/17/02
448. Biosite Weak Due to Short Report; Fundamentals Remain Intact (Pt. 2 of 2), BSTE, 7/12/02
449. Biosite Weak Due to Short Report; Fundamentals Remain Intact (Pt. 1 of 2), BSTE, 7/12/02
450. Merck and Celera Genomics Enter Technology License Agreement, CRA, 7/9/02
451. Large Scale Biology Execution Improving; Business Momentum Continues, LSBC, 7/9/02
452. Invitrogen: Stock May Be Weak Due to Qiagen Pre-announcement, IVGN, 7/3/02
453. Biomet: Raising Estimates Due to Lower Share Count and Reduced Goodwill Expense, BMET, 7/2/02
454. After One-time Charge, Biomet Meets Estimates, BMET, 7/2/02
455. Large Scale Biology Announces Another Sizeable Bio-manufacturing Deal, LSBC, 6/28/02
456. Large Scale Biology Announces Another New Customer for Plurigen, LSBC, 6/26/02
457. Applied Biosystems and Abbott Announce Industry-changing Alliance, ABI, 6/25/02
458. Celera Diagnostics and Abbott Announce Industry-changing Alliance, CRA, 6/25/02
459. Resuming Coverage of Genentech With a Long-term Buy Rating, DNA, 89 pages, 6/13/02
460. Stryker to Close New Jersey Manufacturing Facility Pending Union Negotiations, SYK, 6/12/02
461. Celera Reduces Headcount by 16%, CRA, 6/11/02
462. Large Scale Biology Signs Sizable Bioprocessing Deal, LSBC, 6/10/02
463. Stryker Acquisition of Surgical Dynamics Makes Strategic Sense, SYK, 6/5/02
464. Sangamo to Present Extensive Data at Gene Therapy Conference This Week, SGMO, 6/5/02
465. Large Scale Biology Substantially Reduces Cash Burn by Restructuring Operations, LSBC, 6/5/02
466. Biosite: Reducing Earnings Estimates Due to Increasing Legal Expense Estimates, BSTE, 6/3/02
467. Biosite: Reiterate Buy Rating: Revenue and Earnings Growth Back on Track (II), BSTE, 5/30/02
468. Biosite: Reiterate Buy Rating: Revenue and Earnings Growth Back on Track (I), BSTE, 5/30/02
469. Stryker's Strong, Consistent Performance Continues, SYK, 18 pages, 5/8/02
470. ACLARA Meets Expectations, but Still Awaits Commercialization Traction, ACLA, 5/1/02

471. Celera: Results Indicate Focus Toward Downstream Drug Discovery, CRA, 4/26/02
472. Sangamo: Transition to Early-stage Gene Therapy/Biotechnology Company, SGMO, 4/26/02
473. Applied Biosystems: Outlook for Fiscal 2002 and 2003 Still Uncertain, ABI, 4/26/02
474. Invitrogen First-quarter Earnings Much Better Than Expected, IVGN, 4/26/02
475. Genaissance's Technology and Business Development Gaining Momentum, GNSC, 4/26/02
476. First Look at Celera Genomics' Fiscal Third Quarter 2002 Results, CRA, 4/25/02
477. Large Scale Biology: Deal Pipeline, Cash Burn Improved in First Quarter, LSBC, 4/25/02
478. Biosite: Exceptionally Strong BNP Revenue Growth, as Expected (1/2), BSTE, 4/23/02
479. Biosite: Exceptionally Strong BNP Revenue Growth, as Expected (2/2), BSTE, 4/23/02
480. Applied Biosystems to Become Distributor of Celera's Online Business, CDS, ABI, 4/22/02
481. Kathy Ordonez Appointed as New Celera Genomics President, CRA, 4/22/02
482. Stryker Off to Another Solid and Reliable Start in 2002, SYK, 4/18/02
483. Genomics/Life Sciences Sector Update: Evolution, Not Revolution, ABI, 64 pages, 4/10/02
484. Genomics/Life Sciences Sector Update: Evolution, Not Revolution, CRA, 4/9/02
485. Large Scale Biology Announces Availability of PLURIGEN CM for Sale, LSBC, 3/25/02
486. Modestly Lowering Biomet Estimates, BMET, 3/25/02
487. Very Positive Clinical Trial Results for Biosite's BNP Test for Heart Failure, BSTE, 3/20/02
488. Biosite Announces Discovery Collaboration With Amgen, BSTE, 3/11/02
489. Large Scale Biology Announces Collection of Human Full-length Gene Clones, LSBC, 3/11/02
490. Invitrogen: Modest Execution Issues and Lower Market Growth Reduce Visibility, IVGN, 3/1/02
491. Invitrogen: Weakness Today Due to Court Ruling With Stratagene, IVGN, 2/28/02
492. Biosite: Significant BNP Trial Data to Be Presented at ACC, BSTE, 2/27/02
493. Applied Biosystems and Amersham plc Settle Ongoing Patent Litigation, ABI, 2/26/02
494. ACLARA BioSciences' Fourth-quarter Results Mildly Disappointing, ACLA, 2/20/02
495. Stryker Hosts Upbeat Analyst Meeting, SYK, 2/15/02
496. Biosite's New Antibody Expression Technology Circumvents XOMA Patents, BSTE, 2/14/02
497. ABI.N Applied Biosystems Collaborates With Vanderbilt for Proteomics Application, ABI, 2/12/02
498. Modest Growth Expected for CONMED in 2002, CNMD, 2/6/02
499. Sangamo's Fourth-quarter Achievements Indicate Promising Progress (1 of 2), SGMO, 2/6/02
500. Sangamo's Fourth-quarter Achievements Indicate Promising Progress (2 of 2), SGMO, 2/6/02
501. Genaissance's Business Development Gaining Momentum, GNSC, 2/4/02
502. Large Scale Biology: Quarter Reflects Focusing of Business Development, LSBC, 1/31/02
503. Solid Earnings Growth Performance From Stryker Continues, SYK, 1/29/02
504. Biosite: Operating Expense Overruns Reduce Earnings Outlook in 2002, BSTE, 1/25/02
505. Applied Biosystems: Despite Meeting Expectations, Second-half Outlook Weak, ABI, 1/24/02
506. Invitrogen: Potential Buying Opportunity Today on Likely Weakness in ABI, IVGN, 1/24/02
507. Celera Genomics' Second-quarter Results Again Promising, CRA, 1/24/02
508. Celera Genomics Should Survive Craig Venter's Resignation Well, CRA, 1/23/02
509. Biosite Gets FDA Approval for Improved Drug Test, BSTE, 1/17/02
510. Applied Biosystems: Brief Summary of Investor Day, ABI, 1/11/02
511. Sangamo Extends Collaboration with Medarex to Access Potential Revenue, SGMO, 1/9/02
512. Applied Biosystems' MALDI TOF/TOF for Proteomics Commercially Available, ABI, 1/8/02
513. Celera Genomics Appoints COO for Celera Therapeutics Business, CRA, 1/7/02
514. Sangamo/Pfizer Paper Identifies Protein Critical for Fat-cell Development, SGMO, 1/2/02
515. Biomet Reports Strong Fiscal Second Quarter 2002 Results, BMET, 12/20/01
516. Celera Clarifies Future Plans at Analyst Meeting, CRA, 12/14/01
517. Large Scale Biology Activities at ASH Conference: Promising, But Early Stage, LSBC, 12/11/01
518. Invitrogen Hosts Upbeat Analyst Meeting; Estimates Increased, IVGN, 12/5/01
519. Applied Biosystems: Update on Growing DNA Forensics Opportunities, ABI, 11/28/01
520. Celera's Analyst Day in London, CRA, 11/27/01
521. Celera Genomics Signs Commercial Subscription to Celera Discovery System, CRA, 11/19/01
522. Celera Genomics' Acquisition of Axys Pharmaceuticals Approved, CRA, 11/19/01
523. Genomics/Life Sciences Sector Valuation Update, CRA, 54 pages, 11/9/01
524. Celera and Inpharmatica Collaborate to Commercialize Celera Edition Biopendium, CRA, 11/8/01
525. ACLARA BioSciences' Third-quarter Results, ACLA, 10/30/01
526. Invitrogen Results Solid as Expected; Upside Possible in 2002, IVGN, 10/26/01

527. Applied Biosystems' First Quarter 2002 Results Slightly Better Than Expected, ABI, 10/25/01
528. Large Scale Meets Expectations: Visibility Needed From Business Development, LSBC, 10/25/01
529. Celera Genomics: First Quarter 2002 Results Significantly Beat Expectations, CRA, 10/25/01
530. Genaissance's Third-quarter Results as Expected, GNSC, 10/24/01
531. Biosite Beats Estimate on Lower Revenue--XOMA Takes Its Toll on Discovery (1/1), BSTE, 10/23/01
532. Biosite Beats Estimate on Lower Revenue--XOMA Takes Its Toll on Discovery (2/2), BSTE, 10/23/01
533. Sangamo Third-quarter Results; First Major Milestone With Edwards Announced, SGMO, 10/19/01
534. CONMED Earnings Slightly Lower Than Expectations, CNMD, 10/19/01
535. Invitrogen Sues Incyte, Alleges Commercialized Proprietary Technologies, IVGN, 10/18/01
536. Stryker's Consistency Continues; New Protein OP-1 Gets FDA Exemption, SYK, 10/18/01
537. Genaissance Announces STRENGTH II Clinical Trial, Adds Merck's Mevacor, GNSC, 10/18/01
538. Insights on Biosite From the Annual ACEP Meeting, BSTE, 10/17/01
539. Pfizer Deal Adds Further Validation to GNSC's Haplotype Discovery Technology, GNSC, 10/9/01
540. Genomics Market Capitalization Trends (Part II), BSTE, 10/8/01
541. Genomics Market Capitalization Trends (Part I), BSTE, 10/8/01
542. Biosite: New England Journal of Medicine Study Very Promising, BSTE, 10/5/01
543. Biosite Preliminary Injunction Argument Too Light; XOMA Settlement Out of Sight, BSTE, 9/25/01
544. Invitrogen to Provide Full-length Gene Clones to American Home Products, IVGN, 9/25/01
545. Second Milestone for Celera's Sequencing Capacity Taskforce, CRA, 9/25/01
546. Biomet Off to Strong Start in Fiscal 2002, BMET, 9/20/01
547. Applied Biosystems' API 4000 Mass Spec Update as Expected, ABI, 9/19/01
548. Stryker Added to William Blair & Company's Current Better Values, SYK, 9/19/01
549. Celera Genomics Added to William Blair Current Better Values List, CRA, 9/19/01
550. Large Scale Biology Issued Protein Patent for Plant Technology, LSBC, 9/6/01
551. ACLARA Focuses on Arteas Product Commercialization and ETags' Development, ACLA, 9/6/01
552. Our Visit to Quest Diagnostics Reaffirms Applied Biosystems' Leading Position, ABI, 8/31/01
553. Applied Biosystems, Celera Genomics to Create 2,000-SNP Linkage Map, ABI, 8/28/01
554. Biosite Competitor Roche to Launch Heart Failure Marker in Europe by Year-end, BSTE, 8/17/01
555. Celera Genomics Announces Aptamer Research Collaboration With SomaLogic, CRA, 8/17/01
556. Celera Competitor Incyte Genomics to Launch Competitive New Database Offering, CRA, 8/16/01
557. Biosite: Approval of Heart Failure Drug Natreacor Should Boost BNP Awareness, BSTE, 8/13/01
558. Invitrogen Licenses Gene Therapy Technology From Cell Genesys, IVGN, 8/13/01
559. Applied Biosystems Displays Molecular Diagnostics Leadership at Conference, ABI, 8/9/01
560. Applied Biosystems Displays Molecular Diagnostics Leadership at Conference, ABI, 8/9/01
561. Genaissance: Potential Value of STRENGTH Study Enhanced Due to Baycol Withdrawal, GNSC, 8/8/01
562. Biosite's Triage BNP Assay Emphasized at Heart Failure Session at AACC, BSTE, 7/31/01
563. TOF/TOF Mass Spec and ICAT Positively Highlighted at Proteomics Conference, ABI, 7/30/01
564. Invitrogen Crushes Estimates; Earnings Outlook Improved for 2001, IVGN, 7/27/01
565. Applied Biosystems Fourth-quarter Results: Long-term Fundamentals Remain Strong, ABI, 7/27/01
566. Celera Genomics' Fourth-quarter Results; Continues Promising Progress, CRA, 7/27/01
567. Celera Genomics' Fourth-quarter Results; Continues Promising Progress, CRA, 7/27/01
568. ACLARA Reports Quarter; Making Progress With Development Efforts, ACLA, 7/27/01
569. Large Scale Biology Developmental Progress Ahead of Expectations, LSBC, 7/26/01
570. Celera Benefits as Integral Contributor to Applera's Initiative (Part 1 of 2), CRA, 7/25/01
571. Celera Benefits as Integral Contributor to Applera's Initiative (Part 2 of 2), CRA, 7/25/01
572. Applied Biosystems Benefits as Integral Contributor to Applera Initiative (I), ABI, 7/25/01
573. Applied Biosystems Benefits as Integral Contributor to Applera Initiative (II), ABI, 7/25/01
574. Biosite Operating Performance in Line, but Xoma Dispute Weighs, BSTE, 7/25/01
575. Genaissance Maintains Market Leadership Position in Haplotype Discovery, GNSC, 7/25/01
576. Genaissance: Competitive Effort From Celera Genomics Validates Approach, GNSC, 7/24/01
577. Genaissance: Competitive Effort From Celera Genomics Validates Approach, GNSC, 7/24/01
578. Possible Effects of New Orthopedics Spinoff, SYK, 7/23/01
579. Celera Progressing With Human Genome Molecular Function Assignments, CRA, 7/23/01
580. Applera Corporation to Host Conference Call for Genomics Strategy Review, CRA, 7/23/01
581. Sangamo's Second-quarter Accomplishments and Financial Results, SGMO, 7/20/01
582. CONMED's Second-quarter Performance in Line With Our Modest Expectations, CNMD, 7/19/01

583. Applied Biosystems and deCODE Genetics Enter Three-year Bioinformatics Alliance, ABI, 7/19/01
584. Celera Announces Five New Academic Subscribers, CRA, 7/19/01
585. Business Development Activity--Announces Deal With Pharmacia Corporation, SGMO, 7/18/01
586. Stryker: Solid Performance as Expected; Remains Leader in Orthopedics, SYK, 7/18/01
587. Overall Genomics Market Capitalization Trends (Part 1 of 2), CRA, 7/17/01
588. Overall Genomics Market Capitalization Trends (Part 2 of 2), BSTE, 7/17/01
589. Celera Enters Deal With Isis Pharmaceuticals, CRA, 7/17/01
590. Publication Validates Genaissance's Discovery, Understanding of Gene Variation, GNSC, 7/13/01
591. Sangamo Extends Product Platform, SGMO, 7/12/01
592. Celera to Provide "Direct-to-Scientist" Academic Subscriptions via the Internet, CRA, 7/11/01
593. Applied Biosystems Warns of Slow Revenue Growth for Fourth Quarter, ABI, 7/11/01
594. National Cancer Institute Signs Access Agreement With Celera, CRA, 7/10/01
595. Biomet's Fiscal Fourth Quarter In Line With Our Expectations, BMET, 7/10/01
596. Sangamo Completes Gendaq Acquisition, SGMO, 7/6/01
597. Large Scale Biology Issued U.S. Patent in Proteomics, LSBC, 7/6/01
598. Invitrogen's Recently Launched Products Should Continue Business Momentum, IVGN, 7/6/01
599. Sangamo Accessing More Leading Technology: DNA Microarrays for ZFP Selection, SGMO, 7/5/01
600. Sangamo Announces Gendaq Acquisition at William Blair Growth Stock Conference, SGMO, 6/28/01
601. Fundamental Performance of ResMed Supports Current Valuation, RMD, 25 pages, 6/27/01
602. Sangamo Enters Research Collaboration With ZYCOS For Therapeutic ZFP Delivery, SGMO, 6/27/01
603. Invitrogen Sells Chromatography Business to CIPHERGEN; Announces Collaboration, IVGN, 6/26/01
604. Update on Protein Pathway/Interaction Database Efforts by Competitors, LSBC, 6/25/01
605. Celera Signs 13th Commercial Celera Discovery System Subscriber, CRA, 6/25/01
606. Large Scale Biology Announces Deal With Plant Bioscience Ltd., LSBC, 6/21/01
607. Large Scale Biology Formally Announces New Hires for Business Development, LSBC, 6/20/01
608. Biosite Identifies Two Promising Diagnostic Markers for Stroke, BSTE, 6/20/01
609. Genaissance: Personalized Medicine Is Not Individualized Medicine, GNSC, 6/19/01
610. Celera Signs 12th Commercial Subscriber, CRA, 6/15/01
611. Large Scale Biology Competitor Announces Protein Database Effort, LSBC, 6/15/01
612. Initiating coverage of Genaissance Pharmaceuticals with a Buy, or "2, Rating, GNSC, 6/15/01
613. More Potential Value from Sangamo's Potential Gendaq Acquisition, SGMO, 6/14/01
614. Biosite Still Stalked by XOMA, Temporary Restraining Order Not Granted, BSTE, 6/14/01
615. Celera Buys Axys Pharmaceuticals, Further Crystallizing Transition to Medicine, CRA, 6/13/01
616. Biosite's Legal Action Against XOMA Creates Strong Buying Opportunity, BSTE, 6/12/01
617. Sangamo Accesses Potential Therapeutic Revenue Through Medarex Collaboration, SGMO, 6/12/01
618. Biosite Announces First Protein Array Products at LSBC Presentation, BSTE, 6/7/01
619. Large Scale Biology Hosts Meeting to Discuss the Human Protein Index, LSBC, 6/7/01
620. Large Scale Biology's Leadership in Protein Expression Affirmed, LSBC, 6/4/01
621. Large Scale Biology's Leadership in Protein Expression Affirmed, LSBC, 6/4/01
622. Sangamo Announces Positive Preclinical Results for Engineered ZFP, SGMO, 6/1/01
623. Thoughts Regarding Applied Biosystems Arising From ASMS Meeting, ABI, 5/31/01
624. Sangamo Granted Option to Acquire Gendaq, SGMO, 5/30/01
625. Large Scale Biology: New Database From IBM, MDS Proteomics Not Competitive, LSBC, 5/30/01
626. Biosite: Scios Gets Positive Recommendation From FDA for Natrecor, BSTE, 5/29/01
627. Overall Genomics Market Capitalization Trends, ABI, 5/22/01
628. Applied Biosystems in the Clinical Laboratories for Molecular Diagnostics, ABI, 5/18/01
629. The Genomics Industry, CRA, 5/9/01
630. Progress and Evolving Customer Mix for Celera Genomics Group, CRA, 5/8/01
631. Sangamo Validates Regulation of More Than 300 Human Genes, SGMO, 5/7/01
632. Applied Biosystems Continues Developments in Proteomics, ABI, 5/7/01
633. Large Scale Biology Developmental Progress Ahead of Expectations, LSBC, 5/3/01
634. Applied Biosystems Further Establishing Itself for Celera Diagnostics, ABI, 5/2/01
635. ResMed Fiscal Third Quarter 2001 Earnings, RMD, 5/2/01
636. Celera Achieves Another Milestone--Completes Assembly of Mouse Genome, CRA, 4/27/01
637. Celera Remains Well Positioned, CRA, 4/27/01
638. Invitrogen's Quarterly Results Solidly Beat Estimates, IVGN, 4/27/01

639. Applied Biosystems Third-quarter Results Flat on 19% Revenue Growth, ABI, 4/27/01
640. Sangamo: First-quarter Accomplishments and Results Indicate Healthy Progress, SGMO, 4/26/01
641. CONMED: First-quarter Earnings Slightly Ahead of Expectations, CNMD, 4/25/01
642. ACLARA Appoints Senior Vice President of Research and Development, ACLA, 4/25/01
643. Overall Genomics Market Capitalization Trends (2 of 2), ABI, 4/24/01
644. Overall Genomics Market Capitalization Trends (1 of 2), LSBC, 4/24/01
645. Biosite: Outstanding First-quarter Results; Cardiac Business Back On Track, BSTE, 4/20/01
646. Large Scale Biology Delivers First Proteins for High-affinity Antibodies, LSBC, 4/20/01
647. Stryker Off to Great Start in 2001, SYK, 4/19/01
648. Invitrogen Formally Launches I-SAGE Kit, IVGN, 4/12/01
649. Invitrogen Technology Is Leading Platform for High-throughput Gene Cloning, IVGN, 4/11/01
650. Celera to Integrate its Discovery System with Spotfire DecisionSite, CRA, 4/10/01
651. Applied Biosystems' Big Dye 3.0 Dismissed From Dye Case With Amersham Pharmacia, ABI, 4/9/01
652. Applied Biosystems' ICAT Reagent Applied to Proteomics Alliance, ABI, 4/6/01
653. Large Scale Biology: Implications From Myriad Genetics' Proteomics Announcement, LSBC, 4/5/01
654. Biosite Licenses New Cardiac Marker, BSTE, 4/4/01
655. Patent Settlement Emphasizes Proprietary Nature of Invitrogen Products, IVGN, 4/2/01
656. New Antibody Microarray Developed by Biosite, BSTE, 3/23/01
657. Rating and Estimates Cut After Applied Biosystems Warns of Slower Growth, ABI, 3/22/01
658. DNA Forensics Opportunities Continue to Expand for Applied Biosystems, ABI, 3/21/01
659. Invitrogen: Agreement Solidifies Leading Position as Supplier of Gene Clones, IVGN, 3/21/01
660. Biosite's Exciting Triage BNP Highlighted at ACC, BSTE, 3/19/01
661. Celera Announces Arena Pharma as 28th Discovery System Customer, CRA, 3/16/01
662. Sangamo Granted Core ZFP Patent in United Kingdom, SGMO, 3/15/01
663. Biomet Reports Solid Fiscal Third-quarter Earnings, BMET, 3/15/01
664. Biosite Highlights Strong Sales Thus Far in First Quarter 2001, BSTE, 3/13/01
665. Recent Announcements Suggest Invitrogen Executing Integration Strategy, IVGN, 3/9/01
666. Applied Biosystems Signs Nonexclusive License for Versalinx Technology, ABI, 3/8/01
667. Celera: Agreement With Lynx to Build Gene Expression Atlas, CRA, 3/8/01
668. Applied Biosystems Introduces New Products at Pittcon 2001, ABI, 3/8/01
669. Biomet's Analyst Meeting Positive; Fiscal Third-quarter Earnings to Be Strong, BMET, 3/5/01
670. Stryker Hosts Upbeat Analyst Meeting, SYK, 3/5/01
671. Highlighting Two Recent Developments at Celera, CRA, 3/2/01
672. Invitrogen Reports Solid Fourth-quarter Results, IVGN, 3/1/01
673. Applied Biosystems to Ship ICAT Reagents for Proteomics in March, ABI, 2/28/01
674. Invitrogen Continues New Product Launches, IVGN, 2/27/01
675. BSTE-Preliminary Study Suggests New Uses for Triage Drugs of Abuse in Forensics, BSTE, 2/26/01
676. Stryker and Biomet Competitor to Be Spun Off From Bristol-Myers Squibb, SYK, 2/26/01
677. Applied Biosystems: A Clear Leader in DNA Forensics, ABI, 2/26/01
678. First Milestone for Celera Sequencing Task Force Through Diversa Collaboration, CRA, 2/23/01
679. Sangamo Continues Progress of Its First Gene Therapy Product With Edwards, SGMO, 2/23/01
680. ACLARA BioSciences Advances Business Objectives Well in Fourth Quarter, ACLA, 2/23/01
681. OSTE: Osteotech Fourth Quarter 2000 Results Are Disappointing, OSTE, 2/22/01
682. Celera's Leadership Validated, CRA, 2/12/01
683. CONMED Reports Fourth-quarter Results In Line With Reduced Expectations, CNMD, 2/8/01
684. Collaboration with ProdiGene Uses Large Scale Biology's Manufacturing Facility, LSBC, 2/6/01
685. ResMed Reports In Line Fiscal Second-quarter Results, RMD, 2/6/01
686. Cardiology Journal Publishes Two Positive Studies on Biosite's Triage BNP, BSTE, 2/5/01
687. Large Scale Biology Reports 2000 Progress and Results, LSBC, 2/2/01
688. Sangamo BioSciences Year-end 2000 Progress and Results on Track, SGMO, 2/2/01
689. More Thoughts on Large Scale Biology's Exciting Collaboration With Biosite, LSBC, 1/31/01
690. More Thoughts on Biosite's Exciting Collaboration With Large Scale Biology, BSTE, 1/31/01
691. Initiating Coverage of ACLARA BioSciences With Long-term Buy Rating, ACLA, 1/31/01
692. Large Scale Biology and Biosite Discovery Pursue Protein Chips, LSBC, 1/30/01
693. Biosite Discovery and Large Scale Biology Pursue Protein Chips, BSTE, 1/30/01
694. Stryker Fourth Quarter 2000 Results in Line with Expectations, SYK, 1/30/01

695. Outstanding Results for Applied Biosystems Display Strong and Steady Products, ABI, 1/26/01
696. Celera Remains Well-positioned as it Builds Discovery Capabilities, CRA, 1/26/01
697. Biosite: Fourth-quarter Results \$0.02 Ahead of Consensus, BSTE, 1/26/01
698. Applied Biosystems Progresses in Molecular Diagnostics, ABI, 1/24/01
699. CPQ Cooperative Supercomputing Agreement Among Celera, DOE, and Compaq, CRA, 1/22/01
700. Sangamo Kicks Off 2001; Progressing Well, SGMO, 1/22/01
701. Invitrogen Life Technologies Presents New Products at PAG, IVGN, 1/19/01
702. Cooperative Technology Agreement Among Celera Genomics, DOE and Compaq Expected, CRA, 1/19/01
703. Celera Genomics Group Launches Celera Discovery System "Version 3", CRA, 1/18/01
704. Celera Adds Three More Prestigious Academic Subscription Agreements, CRA, 1/10/01
705. Celera Adds Subscription Agreement With Former Rival Genset, CRA, 1/10/01
706. Celera Executes Strategy: Builds Discovery Sciences Management, CRA, 1/10/01
707. Sangamo Expands Into Agricultural Biotechnology, Sets Goals for 2001, SGMO, 1/10/01
708. Invitrogen Subsidiary Signs First Microarray Manufacturer, IVGN, 1/9/01
709. Competitor Antibody Collaboration Validates Biosite Approach, BSTE, 1/8/01
710. Biosite Hosts Upbeat 2001 Guidance Conference Call, BSTE, 1/5/01
711. Biosite and Medarex Announce Collaboration With Eli Lilly, BSTE, 1/4/01
712. Large Scale Biology Announces Completion of Version 1.0 of Human Protein Index, LSBC, 1/4/01
713. Stryker: European Committee Recommends OP-1 for Marketing Approval, SYK, 1/3/01
714. Large Scale Biology Fundamentals Intact; Reiterate Strong Buy, LSBC, 12/20/00
715. Applied Biosystems' Midrange Genetic Analyzer Remains Competitive, ABI, 12/14/00
716. Biomet Reports Solid Fiscal-second-quarter Earnings, BMET, 12/13/00
717. Invitrogen: Integration Plan on Track; Increasing 2001 Estimates Slightly, IVGN, 12/11/00
718. Celera Genomics Group: Scientific Paper Submitted on the Human Genome, CRA, 12/7/00
719. Biosite Discovery Should Benefit from New UltiMab(TM) Technology from Medarex, BSTE, 12/6/00
720. Celera's Collaboration With Diversa, CRA, 12/5/00
721. Invitrogen Announces Layoffs; Merger Integration on Track, IVGN, 12/1/00
722. Applied Biosystems Announces Productivity Improvements for ABI 3700 Sequencer, ABI, 12/1/00
723. Biosite Should Regain Momentum After Early FDA Approval, BSTE, 11/24/00
724. PE Biosystems: Demand for New Proteomics System Well on Track, PEB, 11/24/00
725. Biosite: Early FDA Approval of Triage BNP Test for Congestive Heart Failure, BSTE, 11/22/00
726. Celera Continues to Add Subscription Agreements, CRA, 11/21/00
727. PE Biosystems - More New Products, PEB, 11/21/00
728. Large Scale Biology Commences Study of Non-Hodgkins Lymphoma Vaccine, LSBC, 11/17/00
729. LSBC.N Large Scale Biology Announces Important Protein Milestone, LSBC, 11/16/00
730. Celera Expands Bioinformatics Collaboration with LION Bioscience, CRA, 11/10/00
731. PE Biosystems Hosts Successful Workshop at Annual AMP Meeting, PEB, 11/10/00
732. PE Corporation Hires President of Roche Molecular Systems, ABI, 11/6/00
733. PE Corporation Hires President of Roche Molecular Systems, PEB, 11/6/00
734. PE Biosystems' deCODE Order Illustrates Continued Success of Sequencer Business, PEB, 11/3/00
735. Invitrogen Posts Solid Quarter; Life Technologies Acquisition on Track, IVGN, 11/2/00
736. ResMed Reports Fiscal-first-quarter Results, RMD, 11/1/00
737. Large Scale Biology Protein Patents Protect Proprietary ProGEx, LSBC, 10/31/00
738. Biosite Lowers Guidance After Beating EPS Estimate by \$0.02, BSTE, 10/27/00
739. Celera Well Positioned for Continued Strong Performance, CRA, 10/27/00
740. Stryker, Biomet, and Osteotech Present at NASS Meeting, SYK, 10/27/00
741. PE Biosystems: Outstanding Results Show Strength of New Product Cycle, PEB, 10/27/00
742. Osteotech's Third Quarter in Line With Reduced Expectations, OSTE, 10/26/00
743. Biosite Remains Leader for Rapid Assays in the Emergency Room, BSTE, 10/25/00
744. Invitrogen Well on Track Early With Integration; Expect Solid Quarter, IVGN, 10/24/00
745. CONMED: Third Quarter 2000 Results in Line With Expectations, CNMD, 10/19/00
746. Invitrogen Subsidiary to Supply DNA Clones to Genomic Solutions, IVGN, 10/19/00
747. More Subscriptions and Validation for the Celera Discovery System, CRA, 10/18/00
748. Stryker Reports Solid Third-quarter Results as Expected, SYK, 10/18/00
749. Large Scale Biology: Reiterate Strong Buy, LSBC, 10/18/00
750. Sangamo Reports Solid Third-quarter Results, SGMO, 10/11/00

751. Invitrogen to Create Kits Using GZMO's SAGE Technology, IVGN, 10/11/00
752. Reiterating "1" Rating on Celera for More Risk-tolerant Investors, CRA, 10/9/00
753. Invitrogen and Life Technologies Sales Reps Excited by Combined Portfolio, IVGN, 10/6/00
754. Celera Previews its Soon-to-be-released Next-generation Discovery System, CRA, 10/5/00
755. PE Biosystems Hosts Annual Linkage Seminar at ASHG Conference, PEB, 10/4/00
756. Invitrogen Announces Two Separate Business Lines, IVGN, 10/2/00
757. Sangamo Announces Three-way Collaboration, SGMO, 10/2/00
758. Paper in "Science" Validates Sangamo's Enhanced Technology, SGMO, 9/29/00
759. Celera Announces First Genomics Company Subscription Agreement, CRA, 9/28/00
760. PE Biosystems Highlights TaqMan and Invader SNP Detection Methods at Conference, PEB, 9/27/00
761. Sangamo Announces Collaboration With Rosetta Inpharmatics, SGMO, 9/26/00
762. Substantial Potential in Sangamo's Gene-regulation Products, SGMO, 48 pages, 9/25/00
763. Sangamo Basic Report Highlights Company's Evolution, SGMO, 9/25/00
764. Celera Announces Agreement to Provide Third-party Data, CRA, 9/25/00
765. Biomet Acquires Bioelectron, BMET, 9/25/00
766. Sangamo Announces Collaboration With Merck, SGMO, 9/18/00
767. Celera Genomics Announces Licensing Agreement with Proteome, CRA, 9/14/00
768. Dexter/Life Technologies Shareholders Approve Merger With Invitrogen, IVGN, 9/14/00
769. Large Scale Biology's Technology Validated by Collaboration With Gemini, LSBC, 9/14/00
770. Biomet Posts Solid Fiscal-first-quarter Results, BMET, 9/14/00
771. PE Biosystems Hosts CE Users Meeting, PEB, 9/14/00
772. Celera Announces New Database Product and Other Progress at GSAC, CRA, 9/13/00
773. Celera Presentation Emphasizes Business Definition and Progress, CRA, 9/8/00
774. Sangamo Announces Validation of Its Gene Therapy Approach in a Mouse Model, SGMO, 9/7/00
775. Large Scale Biology: Initiating Coverage With a Strong Buy Rating, LSBC, 9/5/00
776. PE Biosystems Announces Strategic Alliance with Epoch Biosciences, PEB, 8/18/00
777. Sangamo Announces Journal Publication, SGMO, 8/16/00
778. Celera Genomics Group: Craig Venter Presents at Drug Discovery Conference, CRA, 8/15/00
779. PE Biosystems Presents FMAT High-throughput Screening System at Conference, PEB, 8/15/00
780. Sangamo Results Beat Estimates, SGMO, 8/10/00
781. ResMed Posts Solid Fiscal Fourth-quarter Results, RMD, 8/9/00
782. Invitrogen: Dexter to Sell Remaining Coatings Business, IVGN, 7/31/00
783. Celera Competitor Incyte Provides Free Access to Analyzed Public Data, CRA, 7/31/00
784. Biosite Posts Excellent Second Quarter; Beats Consensus Again, BSTE, 7/27/00
785. Invitrogen Reports Solid Second Quarter 2000; Increasing EPS Estimates, IVGN, 7/27/00
786. CONMED Corporation Rating and Estimates Reduced, CNMD, 7/27/00
787. PE Biosystems Reports Strong Top- and Bottom-line Performance, PEB, 7/27/00
788. Invitrogen Reports Strong Second Quarter 2000, \$0.19 EPS Versus \$0.17 Estimate, IVGN, 7/26/00
789. Osteotech Announces Modest Second-quarter Results, OSTE, 7/26/00
790. CONMED Announces Modest Second-quarter Results, CNMD, 7/26/00
791. Stryker Announces Solid Second-quarter Results, SYK, 7/21/00
792. Celera Adds Three Academic Subscribers, CRA, 7/19/00
793. Celera Signs American Home Products to Database Agreement, CRA, 7/17/00
794. PE Biosystems to Change Name to Applied Biosystems, PEB, 7/17/00
795. Celera Adds Harvard University Subscription, CRA, 7/14/00
796. Invitrogen Through Life Technologies Enters Agreement with Celera, IVGN, 7/13/00
797. Celera Announces Another Collaboration Today to Add Additional Revenue, CRA, 7/13/00
798. CONMED EPS Estimates Reduced For 2000 and 2001, CNMD, 7/13/00
799. PE Biosystems & Celera to Supply Gene Expression Reagents for Fruit Fly Genes, ABI, 7/12/00
800. Celera: SNP Consortium and Public Genome Announcement--Too Little, Too Late, CRA, 7/12/00
801. CONMED Preannounces Disappointing Quarterly Results, CNMD, 7/12/00
802. PE Biosystems & Celera to Supply Gene Expression Reagents for Fruit Fly Genes, PEB, 7/12/00
803. Invitrogen's Acquisition of Life Technologies Creates Entry Point, IVGN, 7/11/00
804. Invitrogen Announces Acquisition of Life Technologies/Dexter, IVGN, 7/10/00
805. Biomet Announces Strong Fourth-quarter Results, BMET, 7/7/00
806. Highlights from Biomaterials Conference, BMET, 7/6/00

807. Celera Continues to Build Management Ranks, CRA, 7/5/00
808. Invitrogen Presents at William Blair Growth Stock Conference, IVGN, 6/30/00
809. Stryker Presents at the William Blair & Company Growth Stock Conference, SYK, 6/30/00
810. ResMed Presents at William Blair Growth Stock Conference, RMD, 6/30/00
811. Biosite Presents at William Blair & Company Growth Stock Conference, BSTE, 6/29/00
812. Sangamo Presents at William Blair & Company Growth Stock Conference, SGMO, 6/29/00
813. PE Biosystems Presents at William Blair & Company Growth Stock Conference, PEB, 6/29/00
814. Celera Presents at the William Blair 20th Annual Growth Stock Conference, CRA, 6/28/00
815. More Positive News From Celera News Conference, CRA, 6/26/00
816. Celera Completes Assembly of the Human Genome, CRA, 6/26/00
817. Celera Will Announce Monday That It Has Finished Assembling the Human Genome, CRA, 6/26/00
818. ResMed: Associated Professional Sleep Society Annual Conference Highlights, RMD, 6/26/00
819. ResMed to Reinvest More in New Business Opportunities, RMD, 6/26/00
820. Celera: Real Newsflow May Positively Affect Genomics Space Today, CRA, 6/23/00
821. Invitrogen Acquires ETHROG Biotechnologies, IVGN, 6/22/00
822. Lowering Estimates for Osteotech, OSTE, 6/16/00
823. WSJ Article Suggests Possible Resolution Between Celera & Human Genome Project, CRA, 6/15/00
824. Invitrogen in Collaboration with Affymetrix, IVGN, 6/13/00
825. Celera: Two More Positive Events, CRA, 6/12/00
826. PE Biosystems Hosts Successful User Group Meeting at Mass Spec, PEB, 6/12/00
827. Congressional Testimony Highlights Barrier to New Economy and Celera, CRA, 6/7/00
828. Osteotech Announces Tissue Bank Agreement, OSTE, 6/7/00
829. Sangamo Announces Collaboration With J&J Subsidiary, SGMO, 6/7/00
830. Stryker Acquires Image Guided Technologies, Inc., SYK, 6/2/00
831. Celera Appoints Senior Vice President and Manager of Genomics Services, CRA, 6/2/00
832. Biosite: Biosite Discovery in Substantial Collaboration With Medarex, BSTE, 6/1/00
833. CRA: Celera Unexpectedly Announces Significant Progress in Mouse Sequencing, CRA, 6/1/00
834. CONMED Hires President for Linvatec Subsidiary, CNMD, 5/31/00
835. PE Biosystems Terminates Merger Agreement with Third Wave, PEB, 5/26/00
836. Biomet Announces Bone-grafting Materials Collaboration, BMET, 5/25/00
837. CRA: Celera and Government Genome Projects Near Completion, CRA, 5/25/00
838. PE Biosystems Announces Bioinformatics Agreement With Genomica, PEB, 5/25/00
839. Clarification of Celera News Story Causing Confusion, CRA, 5/24/00
840. Biomet Receives FDA Clearance for Metal-on-Metal Hip Implants Six Months Early, BMET, 5/24/00
841. Recent Developments Positive for ResMed (RMD), RMD, 5/19/00
842. Osteotech Announces Share Repurchase, OSTE, 5/17/00
843. Negative Article on PE Biosystems Creates Attractive Entry Point for Investors, PEB, 5/16/00
844. ResMed Announces Partnership With National Stroke Association, RMD, 5/15/00
845. Formalizing Coverage of Invitrogen Corporation With a Buy Rating, IVGN, 35 pages, 5/11/00
846. Recent Developments Positive for ResMed (RMD), RMD, 5/11/00
847. OSTE: Additional Detail on Salesforce Hiring, OSTE, 5/11/00
848. Celera Announces First Academic Subscriber--Vanderbilt University, CRA, 5/8/00
849. Sangamo Reports Its First Quarter as a Public Company, SGMO, 5/4/00
850. ResMed's Third Quarter 2000 Results Meet Consensus EPS Estimates, RMD, 5/3/00
851. Initiating Coverage of Invitrogen With a Buy, or "2, Rating, IVGN, 5/3/00
852. Initiating Coverage of Sangamo BioSciences With a Speculative Buy Rating, SGMO, 5/1/00
853. Celera Signs Agriculture Agreement, CRA, 4/27/00
854. Celera's Results Confirm That the Company Is Performing Well, CRA, 4/27/00
855. PE Biosystems Beats Estimate and Looks to the Next Wave of Innovative Products, PEB, 4/27/00
856. CONMED Meets First-quarter Consensus With Strong Top-line Growth, CNMD, 4/26/00
857. Detailed Discussion of Osteotech's Disappointing Results, OSTE, 4/26/00
858. PE Biosystems Enters Agreement With Pharmacoepia and Beckton, Dickinson, PEB, 4/26/00
859. Biosite Beats Estimates Again with Strong First-quarter Results, BSTE, 4/25/00
860. PE Biosystems Announces Launch of Midlevel DNA Sequencer, the PRISM 3100, PEB, 4/25/00
861. Stryker Solid Quarter Signals Return to 20% Growth, SYK, 4/19/00
862. Initiating Coverage of Genentech, Inc. With a Long-term Buy Rating, DNA, 44 pages, 4/18/00

863. New Products Exhibited at American Association of Neurological Surgery Meeting, SYK, 4/17/00
864. Celera Announces Fifth Pharmaceutical Customer for Its Databases, CRA, 3/30/00
865. Reiterate Strong Buy for Biosite on Extreme Overreaction, BSTE, 3/27/00
866. Biosite Well on Track Despite FDA Setback, BSTE, 3/27/00
867. Celera Launches Improved Web Site Along With Fruit Fly Genome Publication, CRA, 3/24/00
868. Celera Genomics Completes and Publishes Drosophila Genome, CRA, 3/23/00
869. Biomet's Third-quarter Results, New Product Highlights, BMET, 3/22/00
870. New Stryker Product Highlights From First-annual AAOS Analyst Meeting, SYK, 3/22/00
871. Recent Events Support Investment Thesis for PE Biosystems, PEB, 3/22/00
872. CONMED Launches New Products at AAOS; Estimate Changes, CNMD, 3/21/00
873. Celera Genomics Group Makes Timely Bioinformatics Acquisition, CRA, 3/21/00
874. CONMED Posts Solid Fourth-quarter Results, CNMD, 2/10/00
875. Osteotech Beats EPS Estimate by \$0.01; Competitive Pressures Still Remain, OSTE, 2/10/00
876. Biosite Diagnostics Beats EPS Estimate by \$0.03, BSTE, 2/3/00
877. ResMed Beats Estimates Again, RMD, 2/3/00
878. CONMED Initiates Cartilage Repair Pre-clinical Trial, CNMD, 2/1/00
879. PE Biosystems Should Benefit from Celera's Entry into Proteomics, PEB, 2/1/00
880. CRA: Follow Up to Earnings: Commercialization Infrastructure Now in Place, CRA, 1/28/00
881. Stryker: Reports Strong Fourth-quarter Results, SYK, 1/28/00
882. PE Biosystems: Reports Strong Quarter, PEB, 1/28/00
883. PE Biosystems: Product Pipeline Continues to Strengthen, PEB, 1/26/00
884. Biomet: Increasing Estimates Due to Acquisition, BMET, 12/17/99
885. Formalizing Coverage of Celera Genomics Group, CRA, 58 pages, 12/15/99
886. Formalizing Coverage of PE Biosystems Group With Buy Rating, PEB, 51 pages, 12/13/99
887. New Information for Celera Arising out of William Blair Luncheon, CRA, 12/6/99
888. Initiating Coverage of PE Corp.-Celera Genomics Grp With "1" Rating (Pt 2 of 2), CRA, 11/23/99
889. Initiating Coverage of PE Corp.-Celera Genomics Grp With "1" Rating (Pt 1 of 2), CRA, 11/23/99
890. Initiating Coverage of PE Biosystems Group With a Buy Rating, PEB, 11/23/99
891. Positive News for Biosite from Annual AHA Meeting, BSTE, 11/12/99
892. Stryker Corporation: Granted Two Noteworthy Patents, SYK, 11/3/99
893. ResMed Beats EPS Estimate by \$0.03, RMD, 10/28/99
894. Final Thoughts on Osteotech--Lowering Estimates and Long-term Growth Rate, OSTE, 10/28/99
895. CONMED Shows Strengths in Arthroscopy, Powered Surgical, and Int'l Markets, CNMD, 10/22/99
896. Biosite Far Exceeds Expectations; Estimate Changes, BSTE, 10/21/99
897. Stryker: Reports Solid Third Quarter, SYK, 10/20/99
898. Osteotech: Lowering Earnings and Long-term Growth Expectations, OSTE, 9/28/99
899. Biosite Diagnostics Incorporated Announces Corixa Collaboration, BSTE, 9/21/99
900. The Orthopedic Industry: Continued Profitable Growth, SYK, 49 pages, 9/17/99
901. Summary of Orthopedic Industry Report, OSTE, 9/17/99
902. In Spite of Short-term Price Risk, OSTE Still Well-positioned For Future Growth, OSTE, 9/17/99
903. In Spite of Short-term Price Risk, OSTE Still Well-positioned For Future Growth, OSTE, 9/17/99
904. Review of Biomet's First Quarter, BMET, 9/17/99
905. Stryker Corporation Initiating Coverage with a Strong Buy Rating, SYK, 9/13/99
906. Osteotech, Inc.: Adds Sofamor Danek Executive, OSTE, 9/13/99
907. Initiating Coverage Of Stryker With Buy Rating, SYK, 63 pages, 9/10/99
908. CONMED Business Well on Track in Spite of Stock Weakness, CNMD, 9/10/99
909. Biosite: Company Visit Confirms Progress, BSTE, 9/8/99
910. Biomet, Inc. is an Innovative, Leading Supplier of Orthopedic Devices, BMET, 63 pages, 8/31/99
911. Biomet to Acquire Implant Innovations Inc., BMET, 8/31/99
912. Initiating Coverage of Biomet, Inc. With a Long-term Buy Rating, BMET, 8/31/99
913. Initiating Coverage of Stryker With a "1, or Buy Rating., SYK, 8/31/99
914. Medtronic to Acquire Xomed, XOMD, 8/27/99
915. For Osteotech, Inc., Positive Conclusions from Annual Tissue Bank Meeting, OSTE, 8/24/99
916. We Remain Confident in Xomed Surgical Products Performance, XOMD, 8/17/99
917. ResMed: Reports Strong Quarter; Raising Estimates, RMD, 8/5/99
918. Latest OSTE Patent Lawsuit Involves Two Instrumentation Patents Licensed to SDG, OSTE, 8/3/99

919. Positive Update for Biosite Diagnostics After AACC Meeting, BSTE, 7/28/99
920. CONMED Quarter Health, CNMD, 7/23/99
921. Biosite Diagnostics: Exceeds Estimate by Four Cents on Strong Revenue Growth, BSTE, 7/21/99
922. Xomed Surgical Products: Reports Strong Second Quarter, XOMD, 7/21/99
923. Osteotech, Inc. Q2 Results Meet Expectations; Estimate Change, OSTE, 7/20/99
924. Osteotech: Weakness Due to Very Premature Regulatory Discussions, OSTE, 7/7/99
925. ResMed: Announces Hospital Sales Alliance With 3Ci, RMD, 7/6/99
926. CONMED: Acquires 3M Powered Surgical Instrument Line, CNMD, 7/1/99
927. ResMed Presents at William Blair Growth Stock Conference, RMD, 6/25/99
928. Biosite Diagnostics Presents at William Blair & Company Stock Conference, BSTE, 6/25/99
929. Osteotech, Inc. Buys Versalok Low Back Fixation System, OSTE, 6/24/99
930. CONMED Corporation Expects 10% Internal Revenue Growth, CNMD, 6/24/99
931. Osteotech, Inc. Allograft Competitors Pursue Legal Infighting, OSTE, 6/22/99
932. ResMed, Inc. Continues to Build Position and Identify New Markets, RMD, 31 pages, 6/18/99
933. ResMed, Inc. Reiterate Buy Rating; Estimate Changes, RMD, 6/17/99
934. Biosite: Foundation, Opportunity Strong; Must Re-prove Execution Ability, BSTE, 6/11/99
935. Osteotech: Remains Best Spine Device Investment, OSTE, 6/11/99
936. CONMED: Story Evolving to Top Line Based on New Products, CNMD, 6/11/99
937. Xomed: Possible Upward Earnings Revisions This Year on Revenue Upside, XOMD, 6/11/99
938. Xomed: VTI Launches Attachment to Enable XOMD Straightshot Handpiece, XOMD, 5/21/99
939. Biosite: Limited DOA Competitor Pursuing IPO, BSTE, 5/14/99
940. Osteotech Issued Two Potentially Valuable and Exciting Patents, OSTE, 5/10/99
941. Osteotech: Raising Estimates Following First-quarter Results, OSTE, 4/30/99
942. Initiating Coverage of XOMD with a Long-term Buy Rating, XOMD, 45 pages, 4/27/99
943. Biosite Diagnostics: Reports Results in Line With Prerelease, BSTE, 4/23/99
944. Initiating Coverage of Xomed Surgical Products With a Long-term Buy, or "2", XOMD, 4/23/99
945. CONMED Corporation Estimate Increases, CNMD, 4/21/99
946. Osteotech, Inc. Stock Price Weak on Competitor's Flat First-quarter Sales, OSTE, 4/21/99
947. Exciting New Products for CONMED Corporation, CNMD, 4/7/99
948. Biosite Diagnostics: Final Thoughts on Mixed News, BSTE, 4/1/99
949. CONMED Corporation Continues to Launch New Products, CNMD, 4/1/99
950. Initiating Coverage of CONMED Corporation With a Buy Rating, CNMD, 3/25/99
951. Initiating Coverage of CONMED Corporation With a Long-term Buy Rating, CNMD, 44 pages, 3/23/99
952. Details of the "Biosite Discovery" Program; Reinforce Our Excitement, BSTE, 3/16/99
953. Osteotech's Stock Down on Unfounded Rumor of Common Sales Agents With SDG, OSTE, 3/16/99
954. Biosite Diagnostics Announces Exciting New "Biosite Discovery" Program, BSTE, 3/16/99
955. Momentum Building for Biosite Out of Cardiology Meeting, BSTE, 3/12/99
956. Osteotech, Inc. Weakness Creates Buying Opportunity, OSTE, 3/10/99
957. Weakness Due to Osteotech Patent Lawsuit Creates Buying Opportunity, OSTE, 3/3/99
958. Biosite Diagnostic Inc. Short-term Momentum Possible due to Positive Events, BSTE, 2/26/99
959. Osteotech, Inc. Weakness Creates an Opportunity to Add to Positions, OSTE, 2/18/99
960. Reiterate our Strong Buy Rating and Are Raising Estimates for Biosite, BSTE, 2/9/99
961. Osteotech Closes Acquisition of French Firm, OSTE, 2/2/99
962. Biosite Options to be Listed by CBOE, BSTE, 2/2/99
963. Biosite Licensor to Hear From FDA Regarding Application for New Heart Drug, BSTE, 1/30/99
964. Biosite Licensor's Drug Recommended by FDA Advisory Committee, BSTE, 1/29/99
965. Biosite Licenses Antibody Production and Screening Technology, BSTE, 1/26/99
966. Follow-up on Osteotech's Excellent Fourth-quarter Results, OSTE, 1/25/99
967. Osteotech, Inc. Earnings Should Slightly Exceed Our Estimate, OSTE, 1/21/99
968. Initiating Research Coverage of Biosite Diagnostics With a Strong Buy Rating, BSTE, 12/21/98
969. Initiating Coverage of Biosite Diagnostics With a Strong Buy Rating, BSTE, 63 pages, 12/18/98
970. Osteotech, Inc. Estimates Raised Due to Recent Positive Developments, OSTE, 12/18/98
971. Osteotech Receives New Important Patent, OSTE, 12/10/98
972. Osteotech and Clients Accelerate Marketing Efforts, OSTE, 11/5/98
973. Sofamor Danek Positioned As New Product Development Powerhouse, SDG, 11/2/98
974. Medtronic to Acquire Sofamor Danek Group for \$115 Per Share, SDG, 11/2/98

975. Sofamor Danek Group Posts Strong Third-quarter Results, SDG, 10/22/98
976. Sofamor Danek Reports Strong Quarter; Revenue up 31%, EPS of \$0.64, SDG, 10/22/98
977. Osteotech Reports Strong Third Quarter, With EPS up 57%, OSTE, 10/21/98
978. Wall Street Journal Article Creates Buying Opportunity for Sofamor Danek Group, SDG, 10/8/98
979. Osteotech Weakness Creates Buying Opportunity, OSTE, 10/1/98
980. Initiating Coverage of Osteotech, Inc. with a Buy Rating, OSTE, 9/30/98
981. Initiating Coverage of Osteotech, Inc. With a Buy Rating, OSTE, 55 pages, 9/28/98
982. Sofamor Danek: Xomed to Distribute Specialized StealthStation, SDG, 9/11/98
983. Sofamor Danek Rating, Estimates Increased, SDG, 7/27/98
984. SGD Shows a Strong Quarter, with EPS Increasing 21%, SDG, 7/22/98
985. SDG's Largest Competitor, DePuy, Purchased by J&J, SDG, 7/21/98
986. SDG License Two New Enabling Technologies, SDG, 6/23/98
987. Sofamor Danek Group Competitor Acquired by DePuy, SDG, 6/5/98
988. Initiating Coverage of Sofamor Danek, Inc. With a Long-term Buy Rating, SDG, 64 pages, 5/28/98
989. Initiating Coverage of Sofamor Danek Group With "2" Rating, SDG, 5/26/98